

Senate Engrossed

State of Arizona  
Senate  
Forty-seventh Legislature  
First Regular Session  
2005

CHAPTER 241

## **SENATE BILL 1126**

AN ACT

AMENDING SECTIONS 13-3401, 32-1901, 32-1902, 32-1903, 32-1922, 32-1932.01, 32-1940, 32-1968, 36-2513, 36-2523 AND 36-2525, ARIZONA REVISED STATUTES; REPEALING SECTIONS 32-1927, 32-1927.01 AND 32-1932, ARIZONA REVISED STATUTES; AMENDING TITLE 32, CHAPTER 18, ARTICLE 1, ARIZONA REVISED STATUTES, BY ADDING SECTION 32-1901.01; AMENDING TITLE 32, CHAPTER 18, ARTICLE 2, ARIZONA REVISED STATUTES, BY ADDING NEW SECTIONS 32-1927 AND 32-1927.01 AND SECTION 32-1927.02; RELATING TO THE ARIZONA STATE BOARD OF PHARMACY.

(TEXT OF BILL BEGINS ON NEXT PAGE)

Be it enacted by the Legislature of the State of Arizona:

Section 1. Section 13-3401, Arizona Revised Statutes, is amended to read:

13-3401. Definitions

In this chapter, unless the context otherwise requires:

1. "Administer" means to apply, inject or facilitate the inhalation or ingestion of a substance to the body of a person.

2. "Amidone" means any substance identified chemically as (4-4-diphenyl)-6-dimethylamine-heptanone-3), or any salt of such substance, by whatever trade name designated.

3. "Board" means the Arizona state board of pharmacy.

4. "Cannabis" means the following substances under whatever names they may be designated:

(a) The resin extracted from any part of a plant of the genus cannabis, and every compound, manufacture, salt, derivative, mixture or preparation of such plant, its seeds or its resin. Cannabis does not include oil or cake made from the seeds of such plant, any fiber, compound, manufacture, salt, derivative, mixture or preparation of the mature stalks of such plant except the resin extracted from the stalks or any fiber, oil or cake or the sterilized seed of such plant which is incapable of germination.

(b) Every compound, manufacture, salt, derivative, mixture or preparation of such resin or tetrahydrocannabinol.

5. "Coca leaves" means cocaine, its optical isomers and any compound, manufacture, salt, derivative, mixture or preparation of coca leaves, except derivatives of coca leaves which do not contain cocaine, ecgonine or substances from which cocaine or ecgonine may be synthesized or made.

6. "Dangerous drug" means the following by whatever official, common, usual, chemical or trade name designated:

(a) Any material, compound, mixture or preparation which contains any quantity of the following hallucinogenic substances and their salts, isomers and salts of isomers, unless specifically excepted, whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:

(i) ALPHA-ETHYLTRYPTAMINE.

(ii) AMINOREX.

(iii) 4-BROMO-2, 5-DIMETHOXYPHENETHYLAMINE.

~~(i)~~ (iv) 4-bromo-2, 5-dimethoxyamphetamine.

~~(ii)~~ (v) Bufotenine.

~~(iii)~~ (vi) Diethyltryptamine.

~~(iv)~~ (vii) 2, 5-dimethoxyamphetamine.

~~(v)~~ (viii) Dimethyltryptamine.

~~(vi)~~ (ix) 5-methoxy-3, 4-methylenedioxyamphetamine.

~~(vii)~~ (x) 4-methyl-2, 5-dimethoxyamphetamine.

~~(viii)~~ (xi) Ibogaine.

~~(ix)~~ (xii) Lysergic acid amide.

- ~~{x}~~ (xiii) Lysergic acid diethylamide.
- ~~{xi}~~ (xiv) Mescaline.
- (xv) 4-METHOXYAMPHETAMINE.
- ~~{xii}~~ (xvi) Methoxymethylenedioxyamphetamine (MDA).
- ~~{xiii}~~ (xvii) Methylenedioxyamphetamine (MDA).
- ~~{xiv}~~ (xviii) 3, 4-methylenedioxyamphetamine.
- ~~{xv}~~ (xix) 3, 4-methylenedioxy-n-ethylamphetamine.
- ~~{xvi}~~ (xx) N-ethyl-3-piperidyl benzilate (JB-318).
- ~~{xvii}~~ (xxi) N-hydroxy-3, 4-methylenedioxyamphetamine.
- ~~{xviii}~~ (xxii) N-methyl-3-piperidyl benzilate (JB-336).
- ~~{xix}~~ (xxiii) N-(1-phenylcyclohexyl) ethylamine (PCE).
- ~~{xx}~~ (xxiv) Nabilone.
- ~~{xxi}~~ (xxv) 1-(1-phenylcyclohexyl) pyrrolidine (PHP).
- ~~{xxii}~~ (xxvi) 1-(1-(2-thienyl)-cyclohexyl) piperidine (TCP).
- ~~{xxiii}~~ (xxvii) 1-(1-(2-thienyl)-cyclohexyl) pyrrolidine.
- ~~{xxiv}~~ (xxviii) Para-methoxyamphetamine (PMA).
- ~~{xxv}~~ (xxix) Psilocybin.
- ~~{xxvi}~~ (xxx) Psilocyn.
- ~~{xxvii}~~ (xxxi) Synhexyl.
- ~~{xxviii}~~ (xxxii) Trimethoxyamphetamine (TMA).

(b) Any material, compound, mixture or preparation which contains any quantity of the following substances and their salts, optical isomers, and salts of optical isomers having a potential for abuse associated with a stimulant effect on the central nervous system:

- (i) Amphetamine.
- (ii) Benzphetamine.
- (iii) BUTORPHANOL.
- ~~{iii}~~ (iv) Cathine ((+)-norpseudoephedrine).
- ~~{iv}~~ (v) Chlorphentermine.
- ~~{v}~~ (vi) Clortermine.
- ~~{vi}~~ (vii) Diethylpropion.
- ~~{vii}~~ (viii) Fencamfamin.
- ~~{viii}~~ (ix) Fenethylline.
- ~~{ix}~~ (x) Fenproporex.
- ~~{x}~~ (xi) Mazindol.
- ~~{xi}~~ (xii) Mefenorex.
- ~~{xii}~~ (xiii) Methamphetamine.
- (xiv) METHCATHINONE.
- ~~{xiii}~~ (xv) 4-methylaminorex.
- ~~{xiv}~~ (xvi) Methylphenidate.
- (xvii) MODAFINIL.
- ~~{xv}~~ (xviii) N-ethylamphetamine.
- ~~{xvi}~~ (xix) N, N-dimethylamphetamine.
- ~~{xvii}~~ (xx) Pemoline.
- ~~{xviii}~~ (xxi) Phendimetrazine.

1       ~~(xix)~~ (xxii) Phenmetrazine.  
 2       ~~(xx)~~ (xxiii) Phentermine.  
 3       ~~(xxi)~~ (xxiv) Pipradol.  
 4       ~~(xxii)~~ (xxv) Propylhexedrine.  
 5       ~~(xxiii)~~ (xxvi) Pyrovalerone.  
 6       (xxvii) SIBUTRAMINE.  
 7       ~~(xxiv)~~ (xxviii) Spa ((-)-1-dimethylamino-1,2-diphenylethane).  
 8       (c) Any material, compound, mixture or preparation which contains any  
 9       quantity of the following substances having a potential for abuse associated  
 10      with a depressant effect on the central nervous system:  
 11      (i) Any substance which contains any quantity of a derivative of  
 12      barbituric acid, or any salt of a derivative of barbituric acid, unless  
 13      specifically excepted.  
 14      (ii) Alprazolam.  
 15      (iii) Bromazepam.  
 16      (iv) Camazepam.  
 17      (v) CARISOPRODOL.  
 18      ~~(vi)~~ (vi) Chloral betaine.  
 19      ~~(vii)~~ (vii) Chloral hydrate.  
 20      ~~(viii)~~ (viii) Chlordiazepoxide.  
 21      ~~(ix)~~ (ix) Chlorhexadol.  
 22      ~~(x)~~ (x) Clobazam.  
 23      ~~(xi)~~ (xi) Clonazepam.  
 24      ~~(xii)~~ (xii) Clorazepate.  
 25      ~~(xiii)~~ (xiii) Clotiazepam.  
 26      ~~(xiv)~~ (xiv) Cloxazolam.  
 27      ~~(xv)~~ (xv) Delorazepam.  
 28      ~~(xvi)~~ (xvi) Diazepam.  
 29      (xvii) DICHLORALPHENAZONE.  
 30      ~~(xviii)~~ (xviii) Estazolam.  
 31      ~~(xix)~~ (xix) Ethchlorvynol.  
 32      ~~(xx)~~ (xx) Ethinamate.  
 33      ~~(xxi)~~ (xxi) Ethyl loflazepate.  
 34      ~~(xxii)~~ (xxii) Fenfluramine.  
 35      ~~(xxiii)~~ (xxiii) Fludiazepam.  
 36      ~~(xxiv)~~ (xxiv) Flunitrazepam.  
 37      ~~(xxv)~~ (xxv) Flurazepam.  
 38      ~~(xxvi)~~ (xxvi) Gamma hydroxy butyrate.  
 39      ~~(xxvii)~~ (xxvii) Glutethimide.  
 40      ~~(xxviii)~~ (xxviii) Halazepam.  
 41      ~~(xxix)~~ (xxix) Haloxazolam.  
 42      ~~(xxx)~~ (xxx) Ketamine.  
 43      ~~(xxxi)~~ (xxxi) Ketazolam.  
 44      ~~(xxxii)~~ (xxxii) Loprazolam.  
 45      ~~(xxxiii)~~ (xxxiii) Lorazepam.

- 1       ~~(xxxii)~~ (xxxiv) Lormetazepam.
- 2       ~~(xxxiii)~~ (xxxv) Lysergic acid.
- 3       ~~(xxxiv)~~ (xxxvi) Mebutamate.
- 4       ~~(xxxv)~~ (xxxvii) Mecloqualone.
- 5       ~~(xxxvi)~~ (xxxviii) Medazepam.
- 6       ~~(xxxvii)~~ (xxxix) Meprobamate.
- 7       ~~(xxxviii)~~ (xl) Methaqualone.
- 8       (xli) METHOHEXITAL.
- 9       ~~(xxxix)~~ (xlii) Methypylon.
- 10       ~~(xl)~~ (xliii) Midazolam.
- 11       ~~(xli)~~ (xliv) Nimetazepam.
- 12       ~~(xlii)~~ (xlv) Nitrazepam.
- 13       ~~(xliii)~~ (xlvi) Nordiazepam.
- 14       ~~(xliv)~~ (xlvii) Oxazepam.
- 15       ~~(xlv)~~ (xlviii) Oxazolam.
- 16       ~~(xlvi)~~ (xlix) Paraldehyde.
- 17       ~~(xlvii)~~ (l) Petrichloral.
- 18       ~~(xlviii)~~ (li) Phencyclidine.
- 19       ~~(xlix)~~ (lii) Pinazepam.
- 20       ~~(li)~~ (liii) Prazepam.
- 21       ~~(lii)~~ (liv) Scopolamine.
- 22       ~~(liii)~~ (lv) Sulfondiethylmethane.
- 23       ~~(liiv)~~ (lvi) Sulfonethylmethane.
- 24       ~~(lv)~~ (lvii) Sulfonmethane.
- 25       ~~(lvii)~~ (lviii) Quazepam.
- 26       ~~(lviii)~~ (lix) Temazepam.
- 27       ~~(lix)~~ (lx) Tetrazepam.
- 28       ~~(lxi)~~ (lxi) Tiletamine.
- 29       ~~(lxii)~~ (lxii) Triazolam.
- 30       (lxiii) ZALEPLON.
- 31       ~~(lxiv)~~ (lxiv) Zolazepam.
- 32       (lxv) ZOLPIDEM.

(d) Any material, compound, mixture or preparation which contains any quantity of the following anabolic steroids and their salts, isomers or esters:

- 36       (i) Boldenone.
- 37       (ii) Clostebol (4-chlorotestosterone).
- 38       (iii) Dehydrochloromethyltestosterone.
- 39       (iv) Drostanolone.
- 40       (v) Ethylestrenol.
- 41       (vi) Fluoxymesterone.
- 42       (vii) Formebolone (formebolone).
- 43       (viii) Mesterolone.
- 44       (ix) Methandriol.
- 45       (x) Methandrostenolone (methandienone).

- 1 (xi) Methenolone.
- 2 (xii) Methyltestosterone.
- 3 (xiii) Mibolerone.
- 4 (xiv) Nandrolone.
- 5 (xv) Norethandrolon.
- 6 (xvi) Oxandrolone.
- 7 (xvii) Oxymesterone.
- 8 (xviii) Oxymetholone.
- 9 (xix) Stanolone (4-dihydrotestosterone).
- 10 (xx) Stanozolol.
- 11 (xxi) Testolactone.
- 12 (xxii) Testosterone.
- 13 (xxiii) Trenbolone.

14 7. "Deliver" means the actual, constructive or attempted exchange from  
15 one person to another, whether or not there is an agency relationship.

16 8. "Director" means the director of the department of health services.

17 9. "Dispense" means distribute, leave with, give away, dispose of or  
18 deliver.

19 10. "Drug court program" means a program that is established pursuant  
20 to section 13-3422 by the presiding judge of the superior court in  
21 cooperation with the county attorney in a county for the purpose of  
22 prosecuting, adjudicating and treating drug dependent persons who meet the  
23 criteria and guidelines for entry into the program that are developed and  
24 agreed on by the presiding judge and the prosecutor.

25 11. "Drug dependent person" means a person who is using a substance  
26 that is listed in paragraph 6, 19, 20, 21 or 28 of this section and who is in  
27 a state of psychological or physical dependence, or both, arising from the  
28 use of that substance.

29 12. "Federal act" has the same meaning prescribed in section 32-1901.

30 13. "Isoamidone" means any substance identified chemically as  
31 (4-4-diphenyl-5-methyl-6-dimethylaminoheptanone-3), or any salt of such  
32 substance, by whatever trade name designated.

33 14. "Isonipeccaine" means any substance identified chemically as  
34 (1-methyl-4-phenyl-piperidine-4-carboxylic acid ethyl ester), or any salt of  
35 such substance, by whatever trade name designated.

36 15. "Ketobemidone" means any substance identified chemically as  
37 (4-(3-hydroxyphenyl)-1-methyl-4-piperidylethyl ketone hydrochloride), or any  
38 salt of such substance, by whatever trade name designated.

39 16. "Licensed" or "permitted" means authorized by the laws of this  
40 state to do certain things.

41 17. "Manufacture" means produce, prepare, propagate, compound, mix or  
42 process, directly or indirectly, by extraction from substances of natural  
43 origin or independently by means of chemical synthesis, or by a combination  
44 of extraction and chemical synthesis. Manufacture includes any packaging or  
45 repackaging or labeling or relabeling of containers. Manufacture does not

1 include any producing, preparing, propagating, compounding, mixing,  
2 processing, packaging or labeling done in conformity with applicable state  
3 and local laws and rules by a licensed practitioner incident to and in the  
4 course of his licensed practice.

5 18. "Manufacturer" means a person who manufactures a narcotic or  
6 dangerous drug or other substance controlled by this chapter.

7 19. "Marijuana" means all parts of any plant of the genus cannabis,  
8 from which the resin has not been extracted, whether growing or not, and the  
9 seeds of such plant. Marijuana does not include the mature stalks of such  
10 plant or the sterilized seed of such plant which is incapable of germination.

11 20. "Narcotic drugs" means the following, whether of natural or  
12 synthetic origin and any substance neither chemically nor physically  
13 distinguishable from them:

- 14 (a) Acetyl-alpha-methylfentanyl.
- 15 (b) Acetylmethadol.
- 16 (c) Alfentanil.
- 17 (d) Allylprodine.
- 18 (e) Alphacetylmethadol.
- 19 (f) Alphameprodine.
- 20 (g) Alphamethadol.
- 21 (h) Alpha-methylfentanyl.
- 22 (i) Alpha-methylthiofentanyl.
- 23 (j) Alphaprodine.
- 24 (k) Amidone (methadone).
- 25 (l) Anileridine.
- 26 (m) Benzethidine.
- 27 (n) Benzylfentanyl.
- 28 (o) Betacetylmethadol.
- 29 (p) Beta-hydroxyfentanyl.
- 30 (q) Beta-hydroxy-3-methylfentanyl.
- 31 (r) Betameprodine.
- 32 (s) Betamethadol.
- 33 (t) Betaprodine.
- 34 (u) Bezitramide.
- 35 (v) Buprenorphine and its salts.
- 36 (w) Cannabis.
- 37 (x) Carfentanil.
- 38 (y) Clonitazene.
- 39 (z) Coca leaves.
- 40 (aa) Dextromoramide.
- 41 (bb) Dextropropoxyphene.
- 42 (cc) Diampromide.
- 43 (dd) Diethylthiambutene.
- 44 (ee) Difenoixin.
- 45 (ff) Dihydrocodeine.

1	(gg)	Dimenoxadol.
2	(hh)	Dimepheptanol.
3	(ii)	Dimethylthiambutene.
4	(jj)	Dioxaphetyl butyrate.
5	(kk)	Diphenoxylate.
6	(ll)	Dipipanone.
7	(mm)	Ethylmethylthiambutene.
8	(nn)	Etonitazene.
9	(oo)	Etoxeridine.
10	(pp)	Fentanyl.
11	(qq)	Furethidine.
12	(rr)	Hydroxypethidine.
13	(ss)	Isoamidone (isomethadone).
14	(tt)	<del>Isonipeccaine</del> PETHIDINE (meperidine).
15	(uu)	Ketobemidone.
16	(vv)	Levomethorphan.
17	(ww)	Levomoramide.
18	(xx)	Levophenacymorphan.
19	(yy)	Levorphanol.
20	(zz)	Metazocine.
21	(aaa)	3-methylfentanyl.
22	(bbb)	1-methyl-4-phenyl-4-propionoxypiperidine (MPPP).
23	(ccc)	3-methylthiofentanyl.
24	(ddd)	Morpheridine.
25	(eee)	Noracymethadol.
26	(fff)	Norlevorphanol.
27	(ggg)	Normethadone.
28	(hhh)	Norpipanone.
29	(iii)	Opium.
30	(jjj)	Para-fluorofentanyl.
31	(kkk)	Pentazocine.
32	(lll)	Phenadoxone.
33	(mmm)	Phenampromide.
34	(nnn)	Phenazocine.
35	(ooo)	1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine (PEPAP).
36	(ppp)	Phenomorphan.
37	(qqq)	Phenoperidine.
38	(rrr)	Piminodine.
39	(sss)	Piritramide.
40	(ttt)	Proheptazine.
41	(uuu)	Properidine.
42	(vvv)	Propiram.
43	(www)	Racemethorphan.
44	(xxx)	Racemoramide.
45	(yyy)	Racemorphan.



1 (zzz) REMIFENTANIL.  
2 ~~(zzz)~~ (aaaa) Sufentanil.  
3 ~~(aaaa)~~ (bbbb) Thenylfentanyl.  
4 ~~(bbbb)~~ (cccc) Thiofentanyl.  
5 ~~(cccc)~~ (dddd) Tilidine.  
6 ~~(dddd)~~ (eeee) Trimeperidine.  
7 21. "Opium" means any compound, manufacture, salt, isomer, salt of  
8 isomer, derivative, mixture or preparation of the following, but does not  
9 include apomorphine or any of its salts:  
10 (a) Acetorphine.  
11 (b) Acetyldihydrocodeine.  
12 (c) Benzylmorphine.  
13 (d) Codeine.  
14 (e) Codeine methylbromide.  
15 (f) Codeine-n-oxide.  
16 (g) Cyprenorphine.  
17 (h) Desomorphine.  
18 (i) Dihydromorphine.  
19 (j) Drotebanol.  
20 (k) Ethylmorphine.  
21 (l) Etorphine.  
22 (m) Heroin.  
23 (n) Hydrocodone.  
24 (o) Hydromorphenol.  
25 (p) Hydromorphone.  
26 (q) LEVO-ALPHACETYLMETHADOL.  
27 ~~(q)~~ (r) Methyldesorphine.  
28 ~~(r)~~ (s) Methyldihydromorphine.  
29 ~~(s)~~ (t) Metopon.  
30 ~~(t)~~ (u) Morphine.  
31 ~~(u)~~ (v) Morphine methylbromide.  
32 ~~(v)~~ (w) Morphine methylsulfonate.  
33 ~~(w)~~ (x) Morphine-n-oxide.  
34 ~~(x)~~ (y) Myrophine.  
35 ~~(y)~~ (z) Nalorphine.  
36 ~~(z)~~ (aa) Nicocodeine.  
37 ~~(aa)~~ (bb) Nicomorphine.  
38 ~~(bb)~~ (cc) Normorphine.  
39 ~~(cc)~~ (dd) Oxycodone.  
40 ~~(dd)~~ (ee) Oxymorphone.  
41 ~~(ee)~~ (ff) Pholcodine.  
42 ~~(ff)~~ (gg) Thebacon.  
43 ~~(gg)~~ (hh) Thebaine.

1        22. "Ordinary ephedrine, pseudoephedrine, (-)-norpseudoephedrine or  
2 phenylpropanolamine product" means a product that contains ephedrine,  
3 pseudoephedrine, (-)-norpseudoephedrine or phenylpropanolamine and that is  
4 all of the following:

5        (a) Approved for sale under the federal act.

6        (b) Labeled, advertised and marketed only for an indication that is  
7 approved by the federal food and drug administration.

8        (c) Either:

9        (i) A nonliquid that is sold in package sizes of not more than three  
10 grams of ephedrine, pseudoephedrine, (-)-norpseudoephedrine or  
11 phenylpropanolamine and that is packaged in blister packs containing not more  
12 than two dosage units or, if the use of blister packs is technically  
13 infeasible, that is packaged in unit dose packets or pouches.

14        (ii) A liquid that is sold in package sizes of not more than three  
15 grams of ephedrine, pseudoephedrine, (-)-norpseudoephedrine or  
16 phenylpropanolamine.

17       23. "Peyote" means any part of a plant of the genus *lophophora*, known  
18 as the mescal button.

19       24. "Pharmacy" means a licensed business where drugs are compounded or  
20 dispensed by a licensed pharmacist.

21       25. "Practitioner" means a person licensed to prescribe and administer  
22 drugs.

23       26. "Precursor chemical I" means any material, compound, mixture or  
24 preparation which contains any quantity of the following substances and their  
25 salts, optical isomers or salts of optical isomers:

26        (a) N-acetylanthranilic acid.

27        (b) Anthranilic acid.

28        (c) Ephedrine.

29        (d) Ergotamine.

30        (e) Isosafrole.

31        (f) Lysergic acid.

32        (g) Methylamine.

33        (h) N-ethylephedrine.

34        (i) N-ethylpseudoephedrine.

35        (j) N-methylephedrine.

36        (k) N-methylpseudoephedrine.

37        (l) Norephedrine.

38        (m) (-)-Norpseudoephedrine.

39        (n) Phenylacetic acid.

40        (o) Phenylpropanolamine.

41        (p) Piperidine.

42        (q) Pseudoephedrine.

43       27. "Precursor chemical II" means any material, compound, mixture or  
44 preparation which contains any quantity of the following substances and their  
45 salts, optical isomers or salts of optical isomers:

- (a) 4-cyano-2-dimethylamino-4, 4-diphenyl butane.
- (b) 4-cyano-1-methyl-4-phenylpiperidine.
- (c) Chlorephedrine.
- (d) Chlorpseudoephedrine.
- (e) Ethyl-4-phenylpiperidine-4-carboxylate.
- (f) 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic acid.
- (g) 1-methyl-4-phenylpiperidine-4-carboxylic acid.
- (h) N-formyl amphetamine.
- (i) N-formyl methamphetamine.
- (j) Phenyl-2-propanone.
- (k) 1-piperidinocyclohexane carbonitrile.
- (l) 1-pyrrolidinocyclohexane carbonitrile.

28. "Prescription-only drug" does not include a dangerous drug or narcotic drug but means:

(a) Any drug which because of its toxicity or other potentiality for harmful effect, or the method of its use, or the collateral measures necessary to its use, is not generally recognized among experts, qualified by scientific training and experience to evaluate its safety and efficacy, as safe for use except by or under the supervision of a medical practitioner.

(b) Any drug that is limited by an approved new drug application under the federal act or section 32-1962 to use under the supervision of a medical practitioner.

(c) Every potentially harmful drug, the labeling of which does not bear or contain full and adequate directions for use by the consumer.

(d) Any drug required by the federal act to bear on its label the legend "Caution: Federal law prohibits dispensing without prescription" or "RX only".

29. "Produce" means grow, plant, cultivate, harvest, dry, process or prepare for sale.

30. "Regulated chemical" means the following substances in bulk form that are not a useful part of an otherwise lawful product:

- (a) Acetic anhydride.
- (b) Hypophosphorous acid.
- (c) Iodine.
- (d) Sodium acetate.
- (e) Red phosphorus.
- (f) Gamma butyrolactone (GBL).
- (g) 1, 4-butanediol.
- (h) Butyrolactone.
- (i) 1, 2 butanolide.
- (j) 2-oxanalone.
- (k) Tetrahydro-2-furanone.
- (l) Dihydro-2(3H)-furanone.
- (m) Tetramethylene glycol.

31. "Retailer" means either:

1 (a) A person other than a practitioner who sells any precursor  
2 chemical or regulated chemical to another person for purposes of consumption  
3 and not resale, whether or not the person possesses a permit issued pursuant  
4 to title 32, chapter 18.

5 (b) A person other than a manufacturer or wholesaler who purchases,  
6 receives or acquires more than twenty-four grams of a precursor chemical.

7 32. "Sale" or "sell" means an exchange for anything of value o.  
8 advantage, present or prospective.

9 33. "Sale for personal use" means the retail sale for a legitimate  
10 medical use in a single transaction to an individual customer, to an employer  
11 for dispensing to employees from first aid kits or medicine chests or to a  
12 school for administration pursuant to section 15-344.

13 34. "Scientific purpose" means research, teaching or chemical analysis.

14 35. "Suspicious transaction" means a transaction to which any of the  
15 following applies:

16 (a) A report is required under the federal act.

17 (b) The circumstances would lead a reasonable person to believe that  
18 any person is attempting to possess a precursor chemical or regulated  
19 chemical for the purpose of unlawful manufacture of a dangerous drug or  
20 narcotic drug, based on such factors as the amount involved, the method of  
21 payment, the method of delivery and any past dealings with any participant.

22 (c) The transaction involves payment for precursor or regulated  
23 chemicals in cash or money orders in a total amount of more than two hundred  
24 dollars.

25 (d) The transaction involves a sale, a transfer or furnishing to a  
26 retailer for resale without a prescription of ephedrine, pseudoephedrine,  
27 (-)-norpseudoephedrine or phenylpropanolamine that is not an ordinary  
28 ephedrine, pseudoephedrine, (-)-norpseudoephedrine or phenylpropanolamine  
29 product.

30 36. "Threshold amount" means a weight, market value or other form of  
31 measurement of an unlawful substance as follows:

32 (a) One gram of heroin.

33 (b) Nine grams of cocaine.

34 (c) Seven hundred fifty milligrams of cocaine base or hydrolyzed  
35 cocaine.

36 (d) Four grams or 50 milliliters of PCP.

37 (e) Nine grams of methamphetamine, including methamphetamine in liquid  
38 suspension.

39 (f) Nine grams of amphetamine, including amphetamine in liquid  
40 suspension.

41 (g) One-half milliliter of lysergic acid diethylamide, or in the case  
42 of blotter dosage units fifty dosage units.

43 (h) Two pounds of marijuana.

44 (i) For any combination consisting solely of those unlawful substances  
45 listed in subdivisions (a) through (h) of this paragraph, an amount equal to

1 or in excess of the threshold amount, as determined by the application of  
2 section 13-3420.

3 (j) For any unlawful substance not listed in subdivisions (a) through  
4 (h) of this paragraph or any combination involving any unlawful substance not  
5 listed in subdivisions (a) through (h) of this paragraph, a value of at least  
6 one thousand dollars.

7 37. "Transfer" means furnish, deliver or give away.

8 38. "Vapor-releasing substance containing a toxic substance" means  
9 paint or varnish dispensed by the use of aerosol spray, or any glue, which  
10 releases vapors or fumes containing acetone, volatile acetates, benzene,  
11 butyl alcohol, ethyl alcohol, ethylene dichloride, isopropyl alcohol, methyl  
12 alcohol, methyl ethyl ketone, pentachlorophenol, petroleum ether, toluene,  
13 volatile ketones, isophorone, chloroform, methylene chloride, mesityl oxide,  
14 xylene, cumene, ethylbenzene, trichloroethylene, mibk, miak, mek or diacetone  
15 alcohol or isobutyl nitrite.

16 39. "Weight" unless otherwise specified includes the entire weight of  
17 any mixture or substance that contains a detectable amount of an unlawful  
18 substance. If a mixture or substance contains more than one unlawful  
19 substance, the weight of the entire mixture or substance is assigned to the  
20 unlawful substance that results in the greater offense. If a mixture or  
21 substance contains lysergic acid diethylamide, the offense that results from  
22 the unlawful substance shall be based on the greater offense as determined by  
23 the entire weight of the mixture or substance or the number of blotter dosage  
24 units. For the purposes of this paragraph, "mixture" means any combination  
25 of substances from which the unlawful substance cannot be removed without a  
26 chemical process.

27 40. "Wholesaler" means a person who in the usual course of business  
28 lawfully supplies narcotic drugs, dangerous drugs, precursor chemicals or  
29 regulated chemicals that he himself has not produced or prepared, but not to  
30 a person for the purpose of consumption by the person, whether or not the  
31 wholesaler has a permit that is issued pursuant to title 32, chapter  
32 18. Wholesaler includes a person who sells, delivers or dispenses a  
33 precursor chemical in an amount or under circumstances that would require  
34 registration as a distributor of precursor chemicals under the federal act.

35 Sec. 2. Section 32-1901, Arizona Revised Statutes, is amended to read:

36 32-1901. Definitions

37 In this chapter, unless the context otherwise requires:

38 1. "Administer" means the direct application of a controlled  
39 substance, prescription-only drug, dangerous drug or narcotic drug, whether  
40 by injection, inhalation, ingestion or any other means, to the body of a  
41 patient or research subject by a practitioner or by the practitioner's  
42 authorized agent or the patient or research subject at the direction of the  
43 practitioner.

44 2. "Advertisement" means all representations disseminated in any  
45 manner or by any means, other than by labeling, for the purpose of inducing,

1 or that are likely to induce, directly or indirectly, the purchase of drugs,  
2 devices, poisons or hazardous substances.

3 3. "ADVISORY LETTER" MEANS A NONDISCIPLINARY LETTER TO NOTIFY A  
4 LICENSEE OR PERMITTEE THAT EITHER:

5 (a) WHILE THERE IS INSUFFICIENT EVIDENCE TO SUPPORT DISCIPLINARY  
6 ACTION, THE BOARD BELIEVES THAT CONTINUATION OF THE ACTIVITIES THAT LED TO  
7 THE INVESTIGATION MAY RESULT IN FURTHER BOARD ACTION AGAINST THE LICENSEE OR  
8 PERMITTEE.

9 (b) THE VIOLATION IS A MINOR OR TECHNICAL VIOLATION THAT IS NOT OF  
10 SUFFICIENT MERIT TO WARRANT DISCIPLINARY ACTION.

11 (c) WHILE THE LICENSEE OR PERMITTEE HAS DEMONSTRATED SUBSTANTIAL  
12 COMPLIANCE THROUGH REHABILITATION, REMEDIATION OR REEDUCATION THAT HAS  
13 MITIGATED THE NEED FOR DISCIPLINARY ACTION, THE BOARD BELIEVES THAT  
14 REPETITION OF THE ACTIVITIES THAT LED TO THE INVESTIGATION MAY RESULT IN  
15 FURTHER BOARD ACTION AGAINST THE LICENSEE OR PERMITTEE.

16 ~~3.~~ 4. "Antiseptic", if a drug is represented as such on its label,  
17 means a representation that it is a germicide, except in the case of a drug  
18 purporting to be, or represented as, an antiseptic for inhibitory use as a  
19 wet dressing, ointment or dusting powder or other use that involves prolonged  
20 contact with the body.

21 ~~4.~~ 5. "Authorized officers of the law" means legally empowered peace  
22 officers, compliance officers of the state board of pharmacy and agents of  
23 the division of narcotics enforcement and criminal intelligence of the  
24 department of public safety.

25 ~~5.~~ 6. "Board" or "board of pharmacy" means the Arizona state board of  
26 pharmacy.

27 ~~6.~~ 7. "Color additive" means a material that either:

28 (a) Is any dye, pigment or other substance made by a process of  
29 synthesis or similar artifice, or extracted, isolated or otherwise derived,  
30 with or without intermediate or final change of identity, from any vegetable,  
31 animal, mineral or other source.

32 (b) If added or applied to a drug, or to the human body or any part of  
33 the human body, is capable of imparting color, except that color additive  
34 does not include any material that has been or may be exempted under the  
35 federal act. Color includes black, white and intermediate grays.

36 ~~7.~~ 8. "Compounding" means the preparation, mixing, assembling,  
37 packaging or labeling of a drug by a pharmacist or an intern or pharmacy  
38 technician under the pharmacist's supervision, for the purpose of dispensing  
39 to a patient based on a valid prescription order. Compounding includes the  
40 preparation of drugs in anticipation of prescription orders prepared on  
41 routine, regularly observed prescribing patterns and the preparation of drugs  
42 as an incident to research, teaching or chemical analysis or for  
43 administration by a medical practitioner to the medical practitioner's  
44 patient and not for sale or dispensing. Compounding does not include the  
45 preparation of commercially available products from bulk compounds or the

1 preparation of drugs for sale to pharmacies, practitioners or entities for  
2 the purpose of dispensing or distribution.

3 ~~8-~~ 9. "Compressed medical gas distributor" means a person who holds a  
4 current permit issued by the board to distribute compressed medical gases  
5 pursuant to a compressed medical gas order to compressed medical gas  
6 suppliers and other entities that are registered, licensed or permitted to  
7 use, administer or distribute compressed medical gases.

8 ~~9-~~ 10. "Compressed medical gas order" means an order for compressed  
9 medical gases that is issued by a medical practitioner.

10 ~~10-~~ 11. "Compressed medical gas supplier" means a person who holds a  
11 current permit issued by the board to supply compressed medical gases  
12 pursuant to a compressed medical gas order and only to the consumer or the  
13 patient.

14 ~~11-~~ 12. "Compressed medical gases" means gases and liquid oxygen that  
15 a compressed medical gas distributor or manufacturer has labeled in  
16 compliance with federal law.

17 ~~12-~~ 13. "Controlled substance" means a drug, substance or immediate  
18 precursor identified, defined or listed in title 36, chapter 27, article 2.

19 ~~13-~~ 14. "Corrosive" means any substance that when it comes in contact  
20 with living tissue will cause destruction of tissue by chemical action.

21 ~~14-~~ 15. "Counterfeit drug" means a drug that, or the container or  
22 labeling of which, without authorization, bears the trademark, trade name or  
23 other identifying mark, imprint, number or device, or any likeness of these,  
24 of a manufacturer, distributor or dispenser other than the person who in fact  
25 manufactured, distributed or dispensed that drug.

26 ~~15-~~ 16. "Dangerous drug" has the same meaning prescribed in section  
27 13-3401.

28 17. "DECREE OF CENSURE" MEANS AN OFFICIAL ACTION THAT IS TAKEN BY THE  
29 BOARD AND THAT MAY INCLUDE A REQUIREMENT FOR RESTITUTION OF FEES TO A PATIENT  
30 OR CONSUMER.

31 ~~16-~~ 18. "Deliver" or "delivery" means the actual, constructive or  
32 attempted transfer from one person to another whether or not there is an  
33 agency relationship.

34 ~~17-~~ 19. "Deputy director" means a pharmacist employed by the board and  
35 selected by the executive director to perform duties as prescribed by the  
36 executive director.

37 ~~18-~~ 20. "Device", except as used in paragraph ~~14~~ 15 of this section,  
38 section 32-1965, paragraph 4 and section 32-1967, subsection A, paragraph 15  
39 and subsection C, means instruments, apparatus and contrivances, including  
40 their components, parts and accessories, including all such items under the  
41 federal act, intended either:

42 (a) For use in the diagnosis, cure, mitigation, treatment or  
43 prevention of disease in the human body or other animals.

44 (b) To affect the structure or any function of the human body or other  
45 animals.

1       ~~19.~~ 21. "Direct supervision of a pharmacist" means the pharmacist is  
2 present. If relating to the sale of certain items, direct supervision of a  
3 pharmacist means that a pharmacist determines the legitimacy or advisability  
4 of a proposed purchase of those items.

5       ~~20.~~ 22. "Director" means the director of the division of narcotics  
6 enforcement and criminal investigation of the department of public safety.

7       ~~21.~~ 23. "Dispense" means to deliver to an ultimate user or research  
8 subject by or pursuant to the lawful order of a practitioner, including the  
9 prescribing, administering, packaging, labeling or compounding necessary to  
10 prepare for that delivery.

11       ~~22.~~ 24. "Dispenser" means a practitioner who dispenses.

12       ~~23.~~ 25. "Distribute" means to deliver, other than by administering or  
13 dispensing.

14       ~~24.~~ 26. "Distributor" means a person who distributes.

15       ~~25.~~ 27. "Drug" means:

16       (a) Articles recognized, or for which standards or specifications are  
17 prescribed, in the official compendium.

18       (b) Articles intended for use in the diagnosis, cure, mitigation,  
19 treatment or prevention of disease in the human body or other animals.

20       (c) Articles other than food intended to affect the structure or any  
21 function of the human body or other animals.

22       (d) Articles intended for use as a component of any articles specified  
23 in subdivision (a), (b) or (c) of this paragraph but does not include devices  
24 or their components, parts or accessories.

25       ~~26.~~ 28. "Drug enforcement administration" means the drug enforcement  
26 administration of the United States department of justice or its successor  
27 agency.

28       ~~27.~~ 29. "Drug or device manufacturing" means the production,  
29 preparation, propagation or processing of a drug or device, either directly  
30 or indirectly, by extraction from substances of natural origin or  
31 independently by means of chemical synthesis and includes any packaging or  
32 repackaging of substances or labeling or relabeling of its container and the  
33 promotion and marketing of the same. Drug or device manufacturing does not  
34 include compounding.

35       ~~28.~~ 30. "Economic poison" means any substance that alone, in chemical  
36 combination or in formulation with one or more other substances is a  
37 pesticide within the meaning of the laws of this state or the federal  
38 insecticide, fungicide and rodenticide act and that is used in the  
39 production, storage or transportation of raw agricultural commodities.

40       ~~29.~~ 31. "Established name", with respect to a drug or ingredient of a  
41 drug, means any of the following:

42       (a) The applicable official name.

43       (b) If there is no such name and the drug or ingredient is an article  
44 recognized in an official compendium, then the official title in an official  
45 compendium.



1 (c) If neither subdivision (a) nor (b) of this paragraph applies, then  
2 the common or usual name of such drug.

3 ~~30-~~ 32. "Executive director" means the executive director of the board  
4 of pharmacy.

5 ~~31-~~ 33. "Federal act" means the federal laws and regulations that  
6 pertain to drugs, devices, poisons and hazardous substances and that are  
7 official at the time any drug, device, poison or hazardous substance is  
8 affected by this chapter.

9 ~~32-~~ 34. "Full service wholesale permittee" means a permittee who may  
10 distribute prescription-only drugs and devices, controlled substances and  
11 over-the-counter drugs and devices to pharmacies or other legal outlets from  
12 a place devoted in whole or in part to wholesaling these items.

13 ~~33-~~ 35. "Graduate intern" means a person who has graduated from a  
14 college, school or program of pharmacy approved by the board and who meets  
15 the qualifications and experience for a pharmacy intern as provided in  
16 section 32-1923.

17 ~~34-~~ 36. "Highly toxic" means any substance that falls within any of  
18 the following categories:

19 (a) Produces death within fourteen days in half or more than half of a  
20 group of ten or more laboratory white rats each weighing between two hundred  
21 and three hundred grams, at a single dose of fifty milligrams or less per  
22 kilogram of body weight, when orally administered.

23 (b) Produces death within fourteen days in half or more than half of a  
24 group of ten or more laboratory white rats each weighing between two hundred  
25 and three hundred grams, if inhaled continuously for a period of one hour or  
26 less at an atmospheric concentration of two hundred parts per million by  
27 volume or less of gas or vapor or two milligrams per liter by volume or less  
28 of mist or dust, provided the concentration is likely to be encountered by  
29 humans if the substance is used in any reasonably foreseeable manner.

30 (c) Produces death within fourteen days in half or more than half of a  
31 group of ten or more rabbits tested in a dosage of two hundred milligrams or  
32 less per kilogram of body weight, if administered by continuous contact with  
33 the bare skin for twenty-four hours or less.

34 If the board finds that available data on human experience with any substance  
35 indicate results different from those obtained on animals in the dosages or  
36 concentrations prescribed in this paragraph, the human data shall take  
37 precedence.

38 ~~35-~~ 37. "Hospital" means any institution for the care and treatment of  
39 the sick and injured that is approved and licensed as a hospital by the  
40 department of health services.

41 ~~36-~~ 38. "Intern" means a pharmacy intern and a graduate intern.

42 ~~37-~~ 39. "Internship" means the practical, experiential, hands-on  
43 training of a pharmacy intern under the supervision of a preceptor.

1       ~~38.~~ 40. "Irritant" means any substance, other than a corrosive, that  
2 on immediate, prolonged or repeated contact with normal living tissue will  
3 induce a local inflammatory reaction.

4       ~~39.~~ 41. "Jurisprudence examination" means a board approved pharmacy  
5 law examination that is written and administered in cooperation with the  
6 national association of boards of pharmacy or another board approved pharmacy  
7 law examination.

8       ~~40.~~ 42. "Label" means a display of written, printed or graphic matter  
9 on the immediate container of any article that, unless easily legible through  
10 the outside wrapper or container, also appears on the outside wrapper or  
11 container of the article's retail package. For the purposes of this  
12 paragraph, the immediate container does not include package liners.

13       ~~41.~~ 43. "Labeling" means all labels and other written, printed or  
14 graphic matter either:

15       (a) On any article or any of its containers or wrappers.

16       (b) Accompanying that article.

17       44. "LETTER OF REPRIMAND" MEANS A DISCIPLINARY LETTER THAT IS A PUBLIC  
18 DOCUMENT ISSUED BY THE BOARD AND THAT INFORMS A LICENSEE OR PERMITTEE THAT  
19 THE LICENSEE'S OR PERMITTEE'S CONDUCT VIOLATES STATE OR FEDERAL LAW AND MAY  
20 REQUIRE THE BOARD TO MONITOR THE LICENSEE OR PERMITTEE.

21       ~~42.~~ 45. "Limited service pharmacy" means a pharmacy approved by the  
22 board to practice a limited segment of pharmacy as indicated by the permit  
23 issued by the board.

24       ~~43.~~ 46. "Manufacture" or "manufacturer" means every person who  
25 prepares, derives, produces, compounds, processes, packages or repackages or  
26 labels any drug in a place, other than a pharmacy, devoted to manufacturing  
27 the drug.

28       ~~44.~~ 47. "Marijuana" has the same meaning prescribed in section  
29 13-3401.

30       ~~45.~~ 48. "Medical practitioner" means any medical doctor, doctor of  
31 osteopathy, dentist, podiatrist, veterinarian or other person licensed and  
32 authorized by law to use and prescribe drugs and devices for the treatment of  
33 sick and injured human beings or animals or for the diagnosis or prevention  
34 of sickness in human beings or animals in this state or any state, territory  
35 or district of the United States.

36       ~~46.~~ 49. "Medication order" means a written or verbal order from a  
37 medical practitioner or that person's authorized agent to administer a drug  
38 or device.

39       ~~47.~~ 50. "Narcotic drug" has the same meaning prescribed in section  
40 13-3401.

41       ~~48.~~ 51. "New drug" means either:

42       (a) Any drug the composition of which is such that the drug is not  
43 generally recognized among experts qualified by scientific training and  
44 experience to evaluate the safety and effectiveness of drugs as safe and

1 effective for use under the conditions prescribed, recommended or suggested  
2 in the labeling.

3 (b) Any drug the composition of which is such that the drug, as a  
4 result of investigations to determine its safety and effectiveness for use  
5 under such conditions, has become so recognized, but that has not, other than  
6 in the investigations, been used to a material extent or for a material time  
7 under those conditions.

8 ~~49.~~ 52. "Nonprescription drug" or "over-the-counter drug" means any  
9 nonnarcotic medicine or drug that may be sold without a prescription and is  
10 prepackaged and labeled for use by the consumer in accordance with the  
11 requirements of the laws of this state and federal law. Nonprescription drug  
12 does not include:

13 (a) A drug that is primarily advertised and promoted professionally to  
14 medical practitioners and pharmacists by manufacturers or primary  
15 distributors.

16 (b) A controlled substance.

17 (c) A drug that is required to bear a label that states "Rx only."

18 (d) A drug intended for human use by hypodermic injection.

19 ~~50.~~ 53. "Nonprescription drug wholesale permittee" means a permittee  
20 who may distribute only over-the-counter drugs and devices to pharmacies or  
21 other lawful outlets from a place devoted in whole or in part to wholesaling  
22 these items.

23 ~~51.~~ 54. "Notice" means personal service or the mailing of a copy of  
24 the notice by certified mail addressed either to the person at the person's  
25 latest address of record in the board office or to the person's attorney.

26 ~~52.~~ 55. "Official compendium" means the latest revision of the United  
27 States pharmacopeia and the national formulary or any current supplement.

28 ~~53.~~ 56. "Other jurisdiction" means one of the other forty-nine states,  
29 the District of Columbia, the Commonwealth of Puerto Rico or a territory of  
30 the United States of America.

31 ~~54.~~ 57. "Package" means a receptacle defined or described in the  
32 United States pharmacopeia and the national formulary as adopted by the  
33 board.

34 ~~55.~~ 58. "Packaging" means the act or process of placing a drug item or  
35 device in a container for the purpose or intent of dispensing or distributing  
36 the item or device to another.

37 ~~56.~~ 59. "Person" means an individual, partnership, corporation and  
38 association, and their duly authorized agents.

39 ~~57.~~ 60. "Pharmaceutical care" means the provision of drug therapy and  
40 other pharmaceutical patient care services.

41 ~~58.~~ 61. "Pharmacist" means an individual currently licensed by the  
42 board to practice the profession of pharmacy in this state.

43 ~~59.~~ 62. "Pharmacist in charge" means the pharmacist who is responsible  
44 to the board for a licensed establishment's compliance with the laws and  
45 administrative rules of this state and of the federal government pertaining

1 to the practice of pharmacy, the manufacturing of drugs and the distribution  
2 of drugs and devices.

3 ~~60-~~ 63. "Pharmacist licensure examination" means a board approved  
4 examination that is written and administered in cooperation with the national  
5 association of boards of pharmacy or any other board approved pharmacist  
6 licensure examination.

7 ~~61-~~ 64. "Pharmacy" means any place:

8 (a) Where drugs, devices, poisons or related hazardous substances are  
9 offered for sale at retail.

10 (b) In which the profession of pharmacy is practiced or where  
11 prescription orders are compounded and dispensed.

12 (c) That has displayed on it or in it the words, "pharmacist,"  
13 "pharmaceutical chemist," "apothecary," "druggist," "pharmacy," "drugstore,"  
14 "drugs," "drug sundries" or any of these words or combinations of these  
15 words, or words of similar import either in English or any other language, or  
16 that is advertised by any sign containing any of these words.

17 (d) Where the characteristic symbols of pharmacy or the characteristic  
18 prescription sign "Rx" is exhibited.

19 (e) Or a portion of any building or structure THAT IS leased, used or  
20 controlled by the permittee to conduct the business authorized by the board  
21 at the address for which the permit was issued and that is enclosed and  
22 secured when a pharmacist is not in attendance.

23 ~~62-~~ 65. "Pharmacy intern" means a person who has all of the  
24 qualifications and experience prescribed in section 32-1923.

25 ~~63-~~ 66. "Pharmacy technician" means a person licensed pursuant to this  
26 chapter.

27 ~~64-~~ 67. "Pharmacy technician trainee" means a person licensed pursuant  
28 to this chapter.

29 ~~65-~~ 68. "Poison" or "hazardous substance" includes, but is not limited  
30 to, any of the following if intended and suitable for household use or use by  
31 children:

32 (a) Any substance that, according to standard works on medicine,  
33 pharmacology, pharmacognosy or toxicology, if applied to, introduced into or  
34 developed within the body in relatively small quantities by its inherent  
35 action uniformly produces serious bodily injury, disease or death.

36 (b) A toxic substance.

37 (c) A highly toxic substance.

38 (d) A corrosive substance.

39 (e) An irritant.

40 (f) A strong sensitizer.

41 (g) A mixture of any of the substances described in this paragraph, if  
42 the substance or mixture of substances may cause substantial personal injury  
43 or substantial illness during or as a proximate result of any customary or  
44 reasonably foreseeable handling or use, including reasonably foreseeable  
45 ingestion by children.

(h) A substance designated by the board to be a poison or hazardous substance. This subdivision does not apply to radioactive substances, economic poisons subject to the federal insecticide, fungicide and rodenticide act or the state pesticide act, foods, drugs and cosmetics subject to state laws or the federal act or substances intended for use as fuels when stored in containers and used in the heating, cooking or refrigeration system of a house. This subdivision applies to any substance or article that is not itself an economic poison within the meaning of the federal insecticide, fungicide and rodenticide act or the state pesticide act, but that is a poison or hazardous substance within the meaning of this paragraph by reason of bearing or containing an economic poison or hazardous substance.

~~66-~~ 69. "Practice of pharmacy" means:

(a) Interpreting, evaluating and dispensing prescription orders in the patient's best interests.

(b) Compounding drugs pursuant to or in anticipation of a prescription order.

(c) Labeling of drugs and devices in compliance with state and federal requirements.

(d) Participating in drug selection and drug utilization reviews, drug administration, drug or drug related research and drug therapy monitoring or management.

(e) Providing patient counseling necessary to provide pharmaceutical care.

(f) Properly and safely storing drugs and devices in anticipation of dispensing.

(g) Maintaining required records of drugs and devices.

(h) Offering or performing of acts, services, operations or transactions necessary in the conduct, operation, management and control of a pharmacy.

~~67-~~ 70. "Practitioner" means any physician, dentist, veterinarian, scientific investigator or other person licensed, registered or otherwise permitted to distribute, dispense, conduct research with respect to or administer a controlled substance in the course of professional practice or research in this state, or any pharmacy, hospital or other institution licensed, registered or otherwise permitted to distribute, dispense, conduct research with respect to or administer a controlled substance in the course of professional practice or research in this state.

~~68-~~ 71. "Preceptor" means a pharmacist who is serving as the practical instructor of an intern and complies with section 32-1923.

72. "PRECURSOR CHEMICAL" MEANS A SUBSTANCE THAT IS:

(a) THE PRINCIPAL COMPOUND THAT IS COMMONLY USED OR THAT IS PRODUCED PRIMARILY FOR USE AND THAT IS AN IMMEDIATE CHEMICAL INTERMEDIARY USED OR LIKELY TO BE USED IN THE MANUFACTURE OF A CONTROLLED SUBSTANCE, THE CONTROL OF WHICH IS NECESSARY TO PREVENT, CURTAIL OR LIMIT MANUFACTURE.

(b) LISTED IN SECTION 13-3401, PARAGRAPH 26 OR 27.

~~69-~~ 73. "Prescription" means either a prescription order or a prescription medication.

~~70-~~ 74. "Prescription medication" means any drug, including label and container according to context, that is dispensed pursuant to a prescription order.

~~71-~~ 75. "Prescription-only device" includes:

(a) Any device that is limited by the federal act to use under the supervision of a medical practitioner.

(b) Any device required by the federal act to bear on its label essentially the legend "Rx only".

~~72-~~ 76. "Prescription-only drug" does not include a controlled substance but does include:

(a) Any drug that because of its toxicity or other potentiality for harmful effect, the method of its use, or the collateral measures necessary to its use is not generally recognized among experts, qualified by scientific training and experience to evaluate its safety and efficacy, as safe for use except by or under the supervision of a medical practitioner.

(b) Any drug that is limited by an approved new drug application under the federal act or section 32-1962 to use under the supervision of a medical practitioner.

(c) Every potentially harmful drug, the labeling of which does not bear or contain full and adequate directions for use by the consumer.

(d) Any drug, other than a controlled substance, required by the federal act to bear on its label the legend "Rx only".

~~73-~~ 77. "Prescription order" means either:

(a) An order to a pharmacist for drugs or devices issued and signed by a duly licensed medical practitioner in the authorized course of the practitioner's professional practice.

(b) An order transmitted to a pharmacist through word of mouth, telephone or other means of communication directed by that medical practitioner. Prescription orders received by word of mouth, telephone or other means of communication shall be maintained by the pharmacist pursuant to section 32-1964 and the record so made by the pharmacist constitutes the original prescription order to be dispensed by the pharmacist. This paragraph does not alter or affect laws of this state or any federal act requiring a written prescription order.

78. "PROFESSIONALLY INCOMPETENT" MEANS:

(a) INCOMPETENCE BASED ON A VARIETY OF FACTORS INCLUDING A LACK OF SUFFICIENT PHARMACEUTICAL KNOWLEDGE OR SKILLS OR EXPERIENCE TO A DEGREE LIKELY TO ENDANGER THE HEALTH OF PATIENTS.

(b) WHEN CONSIDERED WITH OTHER INDICATIONS OF PROFESSIONAL INCOMPETENCE, A PHARMACIST, PHARMACY INTERN OR GRADUATE INTERN WHO FAILS TO OBTAIN A PASSING SCORE ON A BOARD APPROVED PHARMACIST LICENSURE EXAMINATION

OR A PHARMACY TECHNICIAN OR PHARMACY TECHNICIAN TRAINEE WHO FAILS TO OBTAIN A PASSING SCORE ON A BOARD APPROVED PHARMACY TECHNICIAN LICENSURE EXAMINATION.

74. 79. "Radioactive substance" means a substance that emits ionizing radiation.

80. "SAFELY ENGAGE IN EMPLOYMENT DUTIES" MEANS THAT A PERMITTEE OR THE PERMITTEE'S EMPLOYEE IS ABLE TO SAFELY ENGAGE IN EMPLOYMENT DUTIES RELATED TO THE MANUFACTURE, SALE, DISTRIBUTION OR DISPENSING OF DRUGS, DEVICES, POISONS, HAZARDOUS SUBSTANCES, CONTROLLED SUBSTANCES OR PRECURSOR CHEMICALS.

75. 81. "Symbol" means the characteristic symbols that have historically identified pharmacy, including "show globes", "mortar and pestle" and the sign "Rx".

76. 82. "Toxic substance" means a substance, other than a radioactive substance, that has the capacity to produce injury or illness in humans through ingestion, inhalation or absorption through any body surface.

77. 83. "Ultimate user" means a person who lawfully possesses a drug or controlled substance for that person's own use, for the use of a member of that person's household or for administering to an animal owned by that person or by a member of that person's household.

~~78. "Unprofessional conduct" means that conduct of a pharmacist or intern that degrades or injures the profession of pharmacy as provided in section 32-1927, subsection B, paragraph 3.~~

Sec. 3. Title 32, chapter 18, article 1, Arizona Revised Statutes, is amended by adding section 32-1901.01, to read:

32-1901.01. Definition of unethical and unprofessional conduct; permittees; licensees

A. IN THIS CHAPTER, UNLESS THE CONTEXT OTHERWISE REQUIRES, FOR THE PURPOSES OF DISCIPLINING A PERMITTEE, "UNETHICAL CONDUCT" MEANS THE FOLLOWING, WHETHER OCCURRING IN THIS STATE OR ELSEWHERE:

1. COMMITTING A FELONY, WHETHER OR NOT INVOLVING MORAL TURPITUDE, OR A MISDEMEANOR INVOLVING MORAL TURPITUDE OR ANY DRUG RELATED OFFENSE. IN EITHER CASE, CONVICTION BY A COURT OF COMPETENT JURISDICTION OR A PLEA OF NO CONTEST IS CONCLUSIVE EVIDENCE OF THE COMMISSION.

2. COMMITTING AN ACT THAT IS SUBSTANTIALLY RELATED TO THE QUALIFICATIONS, FUNCTIONS OR DUTIES OF A PERMITTEE AND THAT DEMONSTRATES EITHER A LACK OF GOOD MORAL CHARACTER OR AN ACTUAL OR POTENTIAL UNFITNESS TO HOLD A PERMIT IN LIGHT OF THE PUBLIC'S SAFETY.

3. WORKING UNDER THE INFLUENCE OF ALCOHOL OR OTHER DRUGS.

4. ADDICTION TO THE USE OF ALCOHOL OR OTHER DRUGS TO SUCH A DEGREE AS TO RENDER THE PERMITTEE UNFIT TO PERFORM THE PERMITTEE'S EMPLOYMENT DUTIES.

5. VIOLATING A FEDERAL OR STATE LAW OR ADMINISTRATIVE RULE RELATING TO THE MANUFACTURE, SALE OR DISTRIBUTION OF DRUGS, DEVICES, POISONS, HAZARDOUS SUBSTANCES OR PRECURSOR CHEMICALS.

6. VIOLATING A FEDERAL OR STATE LAW OR ADMINISTRATIVE RULE RELATING TO MARIJUANA, PRESCRIPTION-ONLY DRUGS, NARCOTICS, DANGEROUS DRUGS, CONTROLLED SUBSTANCES OR PRECURSOR CHEMICALS.

1           7. VIOLATING STATE OR FEDERAL REPORTING OR RECORD KEEPING REQUIREMENTS  
2 ON TRANSACTIONS RELATING TO PRECURSOR CHEMICALS.

3           8. FAILING TO REPORT IN WRITING TO THE BOARD ANY EVIDENCE THAT A  
4 PHARMACIST, PHARMACY INTERN OR GRADUATE INTERN IS OR MAY BE PROFESSIONALLY  
5 INCOMPETENT, IS OR MAY BE GUILTY OF UNPROFESSIONAL CONDUCT OR IS OR MAY BE  
6 MENTALLY OR PHYSICALLY UNABLE SAFELY TO ENGAGE IN THE PRACTICE OF PHARMACY.

7           9. FAILING TO REPORT IN WRITING TO THE BOARD ANY EVIDENCE THAT A  
8 PHARMACY TECHNICIAN OR PHARMACY TECHNICIAN TRAINEE IS OR MAY BE  
9 PROFESSIONALLY INCOMPETENT, IS OR MAY BE GUILTY OF UNPROFESSIONAL CONDUCT OR  
10 IS OR MAY BE MENTALLY OR PHYSICALLY UNABLE SAFELY TO ENGAGE IN THE  
11 PERMISSIBLE ACTIVITIES OF A PHARMACY TECHNICIAN OR PHARMACY TECHNICIAN  
12 TRAINEE.

13          10. FAILING TO REPORT IN WRITING TO THE BOARD ANY EVIDENCE THAT APPEARS  
14 TO SHOW THAT A PERMITTEE OR PERMITTEE'S EMPLOYEE IS OR MAY BE GUILTY OF  
15 UNETHICAL CONDUCT, IS OR MAY BE MENTALLY OR PHYSICALLY UNABLE SAFELY TO  
16 ENGAGE IN EMPLOYMENT DUTIES RELATED TO MANUFACTURING, SELLING, DISTRIBUTING  
17 OR DISPENSING OF DRUGS, DEVICES, POISONS, HAZARDOUS SUBSTANCES, CONTROLLED  
18 SUBSTANCES OR PRECURSOR CHEMICALS OR IS OR MAY BE IN VIOLATION OF THIS  
19 CHAPTER OR A RULE ADOPTED UNDER THIS CHAPTER.

20          11. INTENDING TO SELL, TRANSFER OR DISTRIBUTE, OR TO OFFER FOR SALE,  
21 TRANSFER OR DISTRIBUTION, OR SELLING, TRANSFERRING, DISTRIBUTING OR  
22 DISPENSING OR OFFERING FOR SALE, TRANSFER OR DISTRIBUTION AN IMITATION  
23 CONTROLLED SUBSTANCE, IMITATION OVER-THE-COUNTER DRUG OR IMITATION  
24 PRESCRIPTION-ONLY DRUG AS DEFINED IN SECTION 13-3451.

25          12. DENIAL OR DISCIPLINE OF A PERMITTEE'S PERMIT TO MANUFACTURE, SELL,  
26 DISTRIBUTE OR DISPENSE DRUGS, DEVICES, POISONS, HAZARDOUS SUBSTANCES OR  
27 PRECURSOR CHEMICALS IN ANOTHER JURISDICTION AND THE PERMIT WAS NOT  
28 REINSTATED.

29          13. COMMITTING AN OFFENSE IN ANOTHER JURISDICTION THAT IF COMMITTED IN  
30 THIS STATE WOULD BE GROUNDS FOR DISCIPLINE.

31          14. OBTAINING OR ATTEMPTING TO OBTAIN A PERMIT OR A PERMIT RENEWAL BY  
32 FRAUD, BY MISREPRESENTATION OR BY KNOWINGLY TAKING ADVANTAGE OF THE MISTAKE  
33 OF ANOTHER PERSON OR AN AGENCY.

34          15. WILFULLY MAKING A FALSE REPORT OR RECORD REQUIRED BY THIS CHAPTER,  
35 REQUIRED BY FEDERAL OR STATE LAWS PERTAINING TO DRUGS, DEVICES, POISONS,  
36 HAZARDOUS SUBSTANCES OR PRECURSOR CHEMICALS OR REQUIRED FOR THE PAYMENT FOR  
37 DRUGS, DEVICES, POISONS OR HAZARDOUS SUBSTANCES OR PRECURSOR CHEMICALS OR FOR  
38 SERVICES PERTAINING TO SUCH DRUGS OR SUBSTANCES.

39          16. KNOWINGLY FILING WITH THE BOARD ANY APPLICATION, RENEWAL OR OTHER  
40 DOCUMENT THAT CONTAINS FALSE OR MISLEADING INFORMATION.

41          17. PROVIDING FALSE OR MISLEADING INFORMATION OR OMITTING MATERIAL  
42 INFORMATION IN ANY COMMUNICATION TO THE BOARD OR THE BOARD'S EMPLOYEES OR  
43 AGENTS.



1 18. VIOLATING OR ATTEMPTING TO VIOLATE, DIRECTLY OR INDIRECTLY, OR  
2 ASSISTING IN OR ABETTING THE VIOLATION OF, OR CONSPIRING TO VIOLATE, THIS  
3 CHAPTER.

4 19. VIOLATING A FORMAL ORDER, TERMS OF PROBATION, A CONSENT AGREEMENT  
5 OR A STIPULATION ISSUED OR ENTERED INTO BY THE BOARD OR ITS EXECUTIVE  
6 DIRECTOR PURSUANT TO THIS CHAPTER.

7 20. FAILING TO COMPLY WITH A BOARD SUBPOENA OR FAILING TO COMPLY IN A  
8 TIMELY MANNER WITH A BOARD SUBPOENA WITHOUT PROVIDING ANY EXPLANATION TO THE  
9 BOARD FOR NOT COMPLYING WITH THE SUBPOENA.

10 21. FAILING TO PROVIDE THE BOARD, ITS EMPLOYEES OR AGENTS OR AN  
11 AUTHORIZED FEDERAL OR STATE OFFICIAL CONDUCTING A SITE INVESTIGATION,  
12 INSPECTION OR AUDIT WITH ACCESS TO ANY PLACE FOR WHICH A PERMIT HAS BEEN  
13 ISSUED OR FOR WHICH AN APPLICATION FOR A PERMIT HAS BEEN SUBMITTED.

14 22. FAILING TO NOTIFY THE BOARD OF A CHANGE OF OWNERSHIP, MANAGEMENT OR  
15 PHARMACIST IN CHARGE.

16 23. FAILING TO PROMPTLY PRODUCE ON THE REQUEST OF THE OFFICIAL  
17 CONDUCTING THE SITE INVESTIGATION, INSPECTION OR AUDIT ANY BOOK, RECORD OR  
18 DOCUMENT.

19 24. OVERRULING OR ATTEMPTING TO OVERRULE A PHARMACIST IN MATTERS OF  
20 PHARMACY ETHICS OR INTERPRETING LAWS PERTAINING TO THE PRACTICE OF PHARMACY  
21 OR THE DISTRIBUTION OF DRUGS OR DEVICES.

22 25. DISTRIBUTING PREMIUMS OR REBATES OF ANY KIND IN CONNECTION WITH THE  
23 SALE OF PRESCRIPTION MEDICATION, OTHER THAN TO THE PRESCRIPTION MEDICATION  
24 RECIPIENT.

25 26. FAILING TO MAINTAIN EFFECTIVE CONTROLS AGAINST THE DIVERSION OF  
26 PRECURSOR CHEMICALS TO UNAUTHORIZED PERSONS OR ENTITIES.

27 27. FRAUDULENTLY CLAIMING TO HAVE PERFORMED A SERVICE.

28 28. FRAUDULENTLY CHARGING A FEE FOR A SERVICE.

29 29. ADVERTISING DRUGS OR DEVICES, OR SERVICES PERTAINING TO DRUGS OR  
30 DEVICES, THAT IS UNTRUE OR MISLEADING IN ANY PARTICULAR, AND THAT IS KNOWN,  
31 OR THAT BY THE EXERCISE OF REASONABLE CARE SHOULD BE KNOWN, TO BE UNTRUE OR  
32 MISLEADING.

33 B. IN THIS CHAPTER, UNLESS THE CONTEXT OTHERWISE REQUIRES, FOR THE  
34 PURPOSES OF DISCIPLINING A PHARMACIST, PHARMACY INTERN OR GRADUATE INTERN,  
35 "UNPROFESSIONAL CONDUCT" MEANS THE FOLLOWING, WHETHER OCCURRING IN THIS STATE  
36 OR ELSEWHERE:

37 1. ADDICTION TO THE USE OF ALCOHOL OR OTHER DRUGS TO SUCH A DEGREE AS  
38 TO RENDER THE LICENSEE UNFIT TO PRACTICE THE PROFESSION OF PHARMACY.

39 2. VIOLATING ANY FEDERAL OR STATE LAW, RULE OR REGULATION RELATING TO  
40 THE MANUFACTURE OR DISTRIBUTION OF DRUGS AND DEVICES OR THE PRACTICE OF  
41 PHARMACY.

42 3. DISPENSING A DIFFERENT DRUG OR BRAND OF DRUG IN PLACE OF THE DRUG  
43 OR BRAND OF DRUG ORDERED OR PRESCRIBED WITHOUT THE EXPRESS PERMISSION IN EACH  
44 CASE OF THE ORDERER, OR IN THE CASE OF A PRESCRIPTION ORDER, THE MEDICAL

1 PRACTITIONER. THE CONDUCT PROHIBITED BY THIS PARAGRAPH DOES NOT APPLY TO  
2 SUBSTITUTIONS AUTHORIZED PURSUANT TO SECTION 32-1963.01.

3 4. OBTAINING OR ATTEMPTING TO OBTAIN A LICENSE TO PRACTICE PHARMACY OR  
4 A LICENSE RENEWAL BY FRAUD, BY MISREPRESENTATION OR BY KNOWINGLY TAKING  
5 ADVANTAGE OF THE MISTAKE OF ANOTHER PERSON OR AN AGENCY.

6 5. DENIAL OR DISCIPLINE OF A LICENSEE'S LICENSE TO PRACTICE PHARMACY  
7 IN ANOTHER JURISDICTION AND THE LICENSE WAS NOT REINSTATED.

8 6. CLAIMING PROFESSIONAL SUPERIORITY IN COMPOUNDING OR DISPENSING  
9 PRESCRIPTION ORDERS.

10 7. FAILING TO COMPLY WITH THE MANDATORY CONTINUING PROFESSIONAL  
11 PHARMACY EDUCATION REQUIREMENTS OF SECTIONS 32-1936 AND 32-1937 AND RULES  
12 ADOPTED BY THE BOARD.

13 8. COMMITTING A FELONY, WHETHER OR NOT INVOLVING MORAL TURPITUDE, OR A  
14 MISDEMEANOR INVOLVING MORAL TURPITUDE OR ANY DRUG RELATED OFFENSE. IN EITHER  
15 CASE, CONVICTION BY A COURT OF COMPETENT JURISDICTION OR A PLEA OF NO CONTEST  
16 IS CONCLUSIVE EVIDENCE OF THE COMMISSION.

17 9. WORKING UNDER THE INFLUENCE OF ALCOHOL OR OTHER DRUGS.

18 10. VIOLATING A FEDERAL OR STATE LAW OR ADMINISTRATIVE RULE RELATING TO  
19 MARIJUANA, PRESCRIPTION-ONLY DRUGS, NARCOTICS, DANGEROUS DRUGS, CONTROLLED  
20 SUBSTANCES OR PRECURSOR CHEMICALS WHEN DETERMINED BY THE BOARD OR BY  
21 CONVICTION IN A FEDERAL OR STATE COURT.

22 11. KNOWINGLY DISPENSING A DRUG WITHOUT A VALID PRESCRIPTION ORDER AS  
23 REQUIRED PURSUANT TO SECTION 32-1968, SUBSECTION A.

24 12. KNOWINGLY DISPENSING A DRUG ON A PRESCRIPTION ORDER THAT WAS ISSUED  
25 IN THE COURSE OF THE CONDUCT OF BUSINESS OF DISPENSING DRUGS PURSUANT TO  
26 DIAGNOSIS BY MAIL OR THE INTERNET.

27 13. FAILING TO REPORT IN WRITING TO THE BOARD ANY EVIDENCE THAT A  
28 PHARMACIST, PHARMACY INTERN OR GRADUATE INTERN IS OR MAY BE PROFESSIONALLY  
29 INCOMPETENT, IS OR MAY BE GUILTY OF UNPROFESSIONAL CONDUCT OR IS OR MAY BE  
30 MENTALLY OR PHYSICALLY UNABLE TO SAFELY ENGAGE IN THE PRACTICE OF PHARMACY.

31 14. FAILING TO REPORT IN WRITING TO THE BOARD ANY EVIDENCE THAT A  
32 PHARMACY TECHNICIAN OR PHARMACY TECHNICIAN TRAINEE IS OR MAY BE  
33 PROFESSIONALLY INCOMPETENT, IS OR MAY BE GUILTY OF UNPROFESSIONAL CONDUCT OR  
34 IS OR MAY BE MENTALLY OR PHYSICALLY UNABLE TO SAFELY ENGAGE IN THE  
35 PERMISSIBLE ACTIVITIES OF A PHARMACY TECHNICIAN OR PHARMACY TECHNICIAN  
36 TRAINEE.

37 15. FAILING TO REPORT IN WRITING TO THE BOARD ANY EVIDENCE THAT A  
38 PERMITTEE OR A PERMITTEE'S EMPLOYEE IS OR MAY BE GUILTY OF UNETHICAL CONDUCT  
39 OR IS OR MAY BE IN VIOLATION OF THIS CHAPTER OR A RULE ADOPTED UNDER THIS  
40 CHAPTER.

41 16. COMMITTING AN OFFENSE IN ANOTHER JURISDICTION THAT IF COMMITTED IN  
42 THIS STATE WOULD BE GROUNDS FOR DISCIPLINE.

43 17. KNOWINGLY FILING WITH THE BOARD ANY APPLICATION, RENEWAL OR OTHER  
44 DOCUMENT THAT CONTAINS FALSE OR MISLEADING INFORMATION.

1 18. PROVIDING FALSE OR MISLEADING INFORMATION OR OMITTING MATERIAL  
2 INFORMATION IN ANY COMMUNICATION TO THE BOARD OR THE BOARD'S EMPLOYEES OR  
3 AGENTS.

4 19. VIOLATING OR ATTEMPTING TO VIOLATE, DIRECTLY OR INDIRECTLY, OR  
5 ASSISTING IN OR ABETTING IN THE VIOLATION OF, OR CONSPIRING TO VIOLATE, THIS  
6 CHAPTER.

7 20. VIOLATING A FORMAL ORDER, TERMS OF PROBATION, A CONSENT AGREEMENT  
8 OR A STIPULATION ISSUED OR ENTERED INTO BY THE BOARD OR ITS EXECUTIVE  
9 DIRECTOR PURSUANT TO THIS CHAPTER.

10 21. FAILING TO COMPLY WITH A BOARD SUBPOENA OR FAILING TO COMPLY IN A  
11 TIMELY MANNER WITH A BOARD SUBPOENA WITHOUT PROVIDING ANY EXPLANATION TO THE  
12 BOARD FOR NOT COMPLYING WITH THE SUBPOENA.

13 22. REFUSING WITHOUT JUST CAUSE TO ALLOW AUTHORIZED AGENTS OF THE BOARD  
14 TO EXAMINE DOCUMENTS THAT ARE REQUIRED TO BE KEPT PURSUANT TO THIS CHAPTER OR  
15 TITLE 36.

16 23. PARTICIPATING IN AN ARRANGEMENT OR AGREEMENT TO ALLOW A  
17 PRESCRIPTION ORDER OR A PRESCRIPTION MEDICATION TO BE LEFT AT, PICKED UP  
18 FROM, ACCEPTED BY OR DELIVERED TO A PLACE THAT IS NOT LICENSED AS A PHARMACY.  
19 THIS PARAGRAPH DOES NOT PROHIBIT A PHARMACIST OR A PHARMACY FROM USING AN  
20 EMPLOYEE OR A COMMON CARRIER TO PICK UP PRESCRIPTION ORDERS AT OR DELIVER  
21 PRESCRIPTION MEDICATIONS TO THE OFFICE OR HOME OF A MEDICAL PRACTITIONER, THE  
22 RESIDENCE OF A PATIENT OR A PATIENT'S HOSPITAL.

23 24. PAYING REBATES OR ENTERING INTO AN AGREEMENT FOR THE PAYMENT OF  
24 REBATES TO A MEDICAL PRACTITIONER OR ANY OTHER PERSON IN THE HEALTH CARE  
25 FIELD.

26 25. PROVIDING OR CAUSING TO BE PROVIDED TO A MEDICAL PRACTITIONER  
27 PRESCRIPTION ORDER BLANKS OR FORMS BEARING THE PHARMACIST'S OR PHARMACY'S  
28 NAME, ADDRESS OR OTHER MEANS OF IDENTIFICATION.

29 26. FRAUDULENTLY CLAIMING TO HAVE PERFORMED A PROFESSIONAL SERVICE.

30 27. FRAUDULENTLY CHARGING A FEE FOR A PROFESSIONAL SERVICE.

31 28. FAILING TO REPORT A CHANGE OF THE LICENSEE'S HOME ADDRESS OR  
32 EMPLOYER AS REQUIRED PURSUANT TO SECTION 32-1926.

33 29. FAILING TO REPORT A CHANGE IN THE LICENSEE'S RESIDENCY STATUS AS  
34 REQUIRED PURSUANT TO SECTION 32-1926.01.

35 C. IN THIS CHAPTER, UNLESS THE CONTEXT OTHERWISE REQUIRES, FOR THE  
36 PURPOSES OF DISCIPLINING A PHARMACY TECHNICIAN OR PHARMACY TECHNICIAN  
37 TRAINEE, "UNPROFESSIONAL CONDUCT" MEANS THE FOLLOWING, WHETHER OCCURRING IN  
38 THIS STATE OR ELSEWHERE:

39 1. ADDICTION TO THE USE OF ALCOHOL OR OTHER DRUGS TO SUCH A DEGREE AS  
40 TO RENDER THE LICENSEE UNFIT TO PERFORM THE LICENSEE'S EMPLOYMENT DUTIES.

41 2. VIOLATING A FEDERAL OR STATE LAW OR ADMINISTRATIVE RULE RELATING TO  
42 THE MANUFACTURE OR DISTRIBUTION OF DRUGS OR DEVICES.

43 3. OBTAINING OR ATTEMPTING TO OBTAIN A PHARMACY TECHNICIAN OR PHARMACY  
44 TECHNICIAN TRAINEE LICENSE OR A PHARMACY TECHNICIAN LICENSE RENEWAL BY FRAUD,

1 BY MISREPRESENTATION OR BY KNOWINGLY TAKING ADVANTAGE OF THE MISTAKE OF  
2 ANOTHER PERSON OR AN AGENCY.

3 4. DENIAL OR DISCIPLINE OF A LICENSEE'S LICENSE TO PRACTICE AS A  
4 PHARMACY TECHNICIAN IN ANOTHER JURISDICTION AND THE LICENSE WAS NOT  
5 REINSTATED.

6 5. FAILING TO COMPLY WITH THE MANDATORY CONTINUING PROFESSIONAL  
7 EDUCATION REQUIREMENTS OF SECTION 32-1925, SUBSECTION I AND RULES ADOPTED BY  
8 THE BOARD.

9 6. COMMITTING A FELONY, WHETHER OR NOT INVOLVING MORAL TURPITUDE, OR A  
10 MISDEMEANOR INVOLVING MORAL TURPITUDE OR ANY DRUG RELATED OFFENSE. IN EITHER  
11 CASE, CONVICTION BY A COURT OF COMPETENT JURISDICTION OR A PLEA OF NO CONTEST  
12 IS CONCLUSIVE EVIDENCE OF THE COMMISSION.

13 7. WORKING UNDER THE INFLUENCE OF ALCOHOL OR OTHER DRUGS.

14 8. VIOLATING A FEDERAL OR STATE LAW OR ADMINISTRATIVE RULE RELATING TO  
15 MARIJUANA, PRESCRIPTION-ONLY DRUGS, NARCOTICS, DANGEROUS DRUGS, CONTROLLED  
16 SUBSTANCES OR PRECURSOR CHEMICALS WHEN DETERMINED BY THE BOARD OR BY  
17 CONVICTION IN A FEDERAL OR STATE COURT.

18 9. FAILING TO REPORT IN WRITING TO THE BOARD ANY EVIDENCE THAT A  
19 PHARMACIST, PHARMACY INTERN OR GRADUATE INTERN IS OR MAY BE PROFESSIONALLY  
20 INCOMPETENT, IS OR MAY BE GUILTY OF UNPROFESSIONAL CONDUCT OR IS OR MAY BE  
21 MENTALLY OR PHYSICALLY UNABLE TO SAFELY ENGAGE IN THE PRACTICE OF PHARMACY.

22 10. FAILING TO REPORT IN WRITING TO THE BOARD ANY EVIDENCE THAT A  
23 PHARMACY TECHNICIAN OR PHARMACY TECHNICIAN TRAINEE IS OR MAY BE  
24 PROFESSIONALLY INCOMPETENT, IS OR MAY BE GUILTY OF UNPROFESSIONAL CONDUCT OR  
25 IS OR MAY BE MENTALLY OR PHYSICALLY UNABLE TO SAFELY ENGAGE IN THE  
26 PERMISSIBLE ACTIVITIES OF A PHARMACY TECHNICIAN OR PHARMACY TECHNICIAN  
27 TRAINEE.

28 11. FAILING TO REPORT IN WRITING TO THE BOARD ANY EVIDENCE THAT A  
29 PERMITTEE OR A PERMITTEE'S EMPLOYEE IS OR MAY BE GUILTY OF UNETHICAL CONDUCT  
30 OR IS OR MAY BE IN VIOLATION OF THIS CHAPTER OR A RULE ADOPTED UNDER THIS  
31 CHAPTER.

32 12. COMMITTING AN OFFENSE IN ANOTHER JURISDICTION THAT IF COMMITTED IN  
33 THIS STATE WOULD BE GROUNDS FOR DISCIPLINE.

34 13. KNOWINGLY FILING WITH THE BOARD ANY APPLICATION, RENEWAL OR OTHER  
35 DOCUMENT THAT CONTAINS FALSE OR MISLEADING INFORMATION.

36 14. PROVIDING FALSE OR MISLEADING INFORMATION OR OMITTING MATERIAL  
37 INFORMATION IN ANY COMMUNICATION TO THE BOARD OR THE BOARD'S EMPLOYEES OR  
38 AGENTS.

39 15. VIOLATING OR ATTEMPTING TO VIOLATE, DIRECTLY OR INDIRECTLY, OR  
40 ASSISTING IN OR ABETTING IN THE VIOLATION OF, OR CONSPIRING TO VIOLATE, THIS  
41 CHAPTER.

42 16. VIOLATING A FORMAL ORDER, TERMS OF PROBATION, A CONSENT AGREEMENT  
43 OR A STIPULATION ISSUED OR ENTERED INTO BY THE BOARD OR ITS EXECUTIVE  
44 DIRECTOR PURSUANT TO THIS CHAPTER.

1 17. FAILING TO COMPLY WITH A BOARD SUBPOENA OR FAILING TO COMPLY IN A  
2 TIMELY MANNER WITH A BOARD SUBPOENA WITHOUT PROVIDING ANY EXPLANATION TO THE  
3 BOARD FOR NOT COMPLYING WITH THE SUBPOENA.

4 18. FAILING TO REPORT A CHANGE OF THE LICENSEE'S HOME ADDRESS OR  
5 EMPLOYER AS REQUIRED PURSUANT TO SECTION 32-1926.

6 19. FAILING TO REPORT A CHANGE IN THE LICENSEE'S RESIDENCY STATUS AS  
7 REQUIRED PURSUANT TO SECTION 32-1926.01.

8 Sec. 4. Section 32-1902, Arizona Revised Statutes, is amended to read:  
9 32-1902. Arizona state board of pharmacy; immunity

10 A. ~~There shall be an~~ THE Arizona state board of pharmacy ~~which shall~~  
11 ~~consist~~ IS ESTABLISHED CONSISTING OF ~~five~~ THE FOLLOWING MEMBERS WHO ARE  
12 APPOINTED BY THE GOVERNOR:

13 1. SIX pharmacists at least one of whom ~~shall be~~ IS a pharmacist  
14 employed by a licensed hospital and AT LEAST ONE OF WHOM IS EMPLOYED BY A  
15 COMMUNITY PHARMACY AND ENGAGED IN THE DAY-TO-DAY PRACTICE OF PHARMACY.

16 2. ONE PHARMACY TECHNICIAN.

17 3. Two ~~lay~~ PUBLIC members ~~appointed by the governor pursuant to~~  
18 ~~section 38-211.~~

19 B. ~~No~~ TO BE QUALIFIED FOR APPOINTMENT:

20 1. A pharmacist ~~shall be appointed to the board unless he has been~~  
21 MUST BE licensed as a pharmacist in this state or any other jurisdiction for  
22 a period of AT LEAST ten years and licensed as a pharmacist and a resident in  
23 this state for a period of at least five years immediately ~~prior to~~ BEFORE  
24 the date of appointment.

25 2. ~~The lay members shall have been residents in~~ EACH PUBLIC MEMBER  
26 MUST BE A RESIDENT OF this state for a period of at least five years  
27 immediately ~~prior to~~ BEFORE the date of appointment.

28 3. A PHARMACY TECHNICIAN MUST BE A PRACTICING PHARMACY TECHNICIAN IN  
29 THIS STATE OR ANY OTHER JURISDICTION FOR AT LEAST FIVE YEARS AND BE LICENSED  
30 AS A PHARMACY TECHNICIAN AND A RESIDENT OF THIS STATE FOR AT LEAST FIVE YEARS  
31 IMMEDIATELY BEFORE THE DATE OF APPOINTMENT. A PHARMACY TECHNICIAN APPOINTED  
32 BEFORE JULY 1, 2009 DOES NOT HAVE TO MEET THE MINIMUM FIVE YEAR LICENSURE  
33 REQUIREMENT OF THIS PARAGRAPH.

34 C. Each pharmacist AND PHARMACY TECHNICIAN member shall serve for a  
35 term of five years. ~~The lay PUBLIC members shall serve at the pleasure of~~  
36 ~~the governor. The lay members~~ may serve for a term of five years unless  
37 removed by the governor. The ~~lay~~ PUBLIC members shall after the first of  
38 every year present a written report to the governor. Vacancies occurring on  
39 the board other than by expiration of term of office shall be filled for the  
40 unexpired portion of the term only.

41 ~~B.~~ D. On or before January 15 of each year in which a pharmacist OR A  
42 PHARMACY TECHNICIAN is to be appointed, the ~~secretary~~ EXECUTIVE DIRECTOR of  
43 the ~~Arizona pharmaceutical~~ PHARMACY association OF ARIZONA may submit to the  
44 governor a list of the names of at least seven of its members who have been  
45 nominated by the association, and who meet the requirements as provided in

1 this section for the next occurring vacancy on the board. The governor may  
2 make appointments of licensed pharmacists AND PHARMACY TECHNICIANS to the  
3 board from the nominees on the list or from others having the necessary  
4 qualifications.

5 ~~C.~~ E. Appointees to the board ~~shall~~, within thirty days after their  
6 appointment, ~~SHALL~~ take and subscribe to an oath or affirmation, before a  
7 properly qualified officer, that they will faithfully and impartially perform  
8 the duties of their office. ~~and such~~ THE EXECUTIVE DIRECTOR SHALL FILE THE  
9 oath or affirmation ~~shall be filed~~ with the secretary of state.

10 ~~D.~~ F. Members of the board ~~of pharmacy shall be~~ ARE personally exempt  
11 from suit with respect to all acts done and actions taken in good faith and  
12 in furtherance of this chapter.

13 Sec. 5. Section 32-1903, Arizona Revised Statutes, is amended to read:

14 32-1903. Organization; meetings; quorum; compensation of board;  
15 executive director; compensation; powers and duties

16 A. The board shall annually elect a president and a vice-president  
17 from among its membership, ~~and~~ SELECT an executive director who may or may  
18 not be a member of the board. The executive director ~~may be elected for a~~  
19 ~~term of not to exceed two years and~~ shall serve at the pleasure of the board.

20 B. The president of the board shall preside at all of its meetings.  
21 ~~, and, in his absence,~~ The vice-president shall act IF THE PRESIDENT IS  
22 ABSENT. A majority of the membership of the board ~~shall constitute~~  
23 CONSTITUTES a quorum.

24 C. The executive director ~~shall be~~ IS the executive officer in charge  
25 of the board's office, ~~and shall administer the provisions of this chapter,~~  
26 under the direction of the board. The executive director shall make, keep  
27 and be in charge of all records and record books required to be kept by the  
28 board, including a register of all licensees and registered businesses under  
29 this chapter. The executive director shall attend to the correspondence of  
30 the board and perform other duties the board requires. The executive  
31 director is eligible to receive compensation as determined pursuant to  
32 section 38-611.

33 D. Any member of the board or the executive director may administer  
34 oaths in connection with the duties of the board. The books, registers and  
35 records of the board as made and kept by the executive director or under the  
36 executive director's supervision are prima facie evidence of the matter  
37 therein recorded in any court of law. Members of the board are eligible to  
38 receive compensation in the amount of two hundred dollars for each day of  
39 actual service in the business of the board and reimbursement for all  
40 expenses necessarily and properly incurred in attending meetings of or for  
41 the board.

42 E. The executive director may designate the deputy director to sign  
43 claims and other documents in the executive director's absence. IF THE  
44 EXECUTIVE DIRECTOR DIES, BECOMES INCAPACITATED OR RESIGNS, THE DEPUTY

1 DIRECTOR SHALL SERVE AS THE EXECUTIVE DIRECTOR UNTIL THE BOARD SELECTS A NEW  
2 EXECUTIVE DIRECTOR.

3 F. The executive director may cause to be published reports  
4 summarizing judgments, decrees, court orders and board action which THAT may  
5 have been rendered under this chapter, including the nature of charges and  
6 the disposition of the charges. The executive director may disseminate  
7 information regarding drugs, devices, poisons or hazardous substances in  
8 situations the executive director believes involve imminent danger to health  
9 or gross deception of the consumer and report the results of investigations  
10 carried out under this chapter.

11 Sec. 6. Section 32-1922, Arizona Revised Statutes, is amended to read:  
12 32-1922. Qualifications of applicant; reciprocity; preliminary  
13 equivalency examination; honorary certificate; fee

14 A. An applicant for licensure as a pharmacist shall:

15 1. Be of good moral character.

16 2. Be a graduate of a school or college of pharmacy or department of  
17 pharmacy of a university recognized by the board or qualify under  
18 subsection C- D OF THIS SECTION.

19 3. Have successfully completed, as substantiated by proper affidavits,  
20 a program of practical experience under the direct supervision of a licensed  
21 pharmacist approved by the board.

22 4. Pass the pharmacist licensure examination and jurisprudence  
23 examination approved by the board. An applicant who fails an examination  
24 three times shall petition the board for permission before retaking the  
25 examination. The board shall evaluate the petition and determine whether to  
26 require additional educational training before approving each additional  
27 retake of the examination.

28 5. Pay an application fee prescribed by the board of not more than  
29 five hundred dollars. An applicant for reciprocal licensure shall pay the  
30 fee prescribed in section 32-1924, subsection D.

31 B. The board may license as a pharmacist, without a pharmacist  
32 licensure examination, a person who is licensed as a pharmacist by a  
33 pharmacist licensure examination in some other jurisdiction if that person:

34 1. Produces satisfactory evidence to the board of having had the  
35 required secondary and professional education and training.

36 2. Is possessed of good morals as demanded of applicants for licensure  
37 and relicensure under this chapter.

38 3. Presents proof to the board's satisfaction of initial licensure by  
39 a pharmacist licensure examination substantially equivalent to the pharmacist  
40 licensure examination required by the board and that the applicant holds the  
41 license in good standing.

42 4. Presents proof to the board's satisfaction that any other license  
43 granted to the applicant by any other jurisdiction has not been suspended,  
44 revoked or otherwise restricted for any reason except nonrenewal or for  
45 failure to obtain the required continuing education credits in any

jurisdiction where the applicant is currently licensed but not engaged in the practice of pharmacy.

5. Passes a board approved jurisprudence examination.

C. Subsection B of this section applies only if the jurisdiction in which the person is licensed grants, under like conditions, reciprocal licensure as a pharmacist to a pharmacist licensed by examination in this state.

D. If an applicant for licensure is a graduate of a pharmacy degree program at a school or college of pharmacy that was not recognized by the board at the time of the person's graduation, the applicant shall pass a preliminary equivalency examination approved by the board in order to qualify to take the examinations prescribed in subsection A of this section.

E. The preliminary equivalency examination required pursuant to subsection D of this section shall cover proficiency in English and academic areas the board deems essential to a satisfactory pharmacy curriculum.

F. An applicant who fails the preliminary equivalency examination required pursuant to subsection D of this section shall not retake the preliminary equivalency examination until the applicant files written proof with the board that the applicant has completed additional remedial academic work previously approved by the board to correct deficiencies in the applicant's education that were indicated by the results of the applicant's last preliminary equivalency examination.

G. A pharmacist who has been licensed in this state for at least fifty years shall be granted an honorary certificate of licensure by the board without the payment of the usual renewal fee, but that certificate of licensure does not confer an exemption from any other requirement of this chapter.

H. The board may require a pharmacist who has not been actively engaged in the practice of pharmacy for over one year to serve not more than four hundred hours in an internship training program approved by the board or its designee before the pharmacist may resume the active practice of pharmacy.

I. An applicant must complete the application process within twelve months after submitting the application.

Sec. 7. Repeal

Sections 32-1927, 32-1927.01 and 32-1932, Arizona Revised Statutes, are repealed.

Sec. 8. Title 32, chapter 18, article 2, Arizona Revised Statutes, is amended by adding new sections 32-1927 and 32-1927.01 and section 32-1927.02, to read:

32-1927. Pharmacists; pharmacy interns; graduate interns; disciplinary action

A. A PHARMACIST, PHARMACY INTERN OR GRADUATE INTERN IS SUBJECT TO DISCIPLINARY ACTION BY THE BOARD FOR ANY OF THE FOLLOWING:



1           1. THE BOARD DETERMINES THAT THE LICENSEE HAS COMMITTED AN ACT OF  
2 UNPROFESSIONAL CONDUCT.

3           2. THE LICENSEE IS FOUND BY PSYCHIATRIC EXAMINATION TO BE MENTALLY  
4 UNFIT TO PRACTICE THE PROFESSION OF PHARMACY.

5           3. THE LICENSEE IS FOUND TO BE PHYSICALLY OR MENTALLY INCAPACITATED TO  
6 SUCH A DEGREE AS TO RENDER THE LICENSEE UNFIT TO PRACTICE THE PROFESSION OF  
7 PHARMACY.

8           4. THE LICENSEE IS FOUND TO BE PROFESSIONALLY INCOMPETENT TO SUCH A  
9 DEGREE AS TO RENDER THE LICENSEE UNFIT TO PRACTICE THE PROFESSION OF  
10 PHARMACY.

11          5. THE LICENSE WAS ISSUED THROUGH ERROR.

12          B. A PHARMACIST, PHARMACY INTERN OR GRADUATE INTERN WHO AFTER A FORMAL  
13 HEARING IS FOUND BY THE BOARD TO BE GUILTY OF UNPROFESSIONAL CONDUCT, TO BE  
14 MENTALLY OR PHYSICALLY UNABLE SAFELY TO ENGAGE IN THE PRACTICE OF PHARMACY OR  
15 TO BE PROFESSIONALLY INCOMPETENT IS SUBJECT TO ANY ONE OR COMBINATION OF THE  
16 FOLLOWING:

17           1. A CIVIL PENALTY OF NOT TO EXCEED ONE THOUSAND DOLLARS FOR EACH  
18 VIOLATION OF THIS CHAPTER OR A RULE ADOPTED UNDER THIS CHAPTER.

19           2. A LETTER OF REPRIMAND.

20           3. A DECREE OF CENSURE.

21           4. PROBATION.

22           5. SUSPENSION OR REVOCATION OF THE LICENSE.

23          C. THE BOARD MAY CHARGE THE COSTS OF FORMAL HEARINGS TO THE LICENSEE  
24 WHO IT FINDS TO BE IN VIOLATION OF THIS CHAPTER OR A RULE ADOPTED UNDER THIS  
25 CHAPTER.

26          D. THE BOARD ON ITS OWN MOTION MAY INVESTIGATE ANY EVIDENCE THAT  
27 APPEARS TO SHOW THAT A PHARMACIST, PHARMACY INTERN OR GRADUATE INTERN IS OR  
28 MAY BE PROFESSIONALLY INCOMPETENT, IS OR MAY BE GUILTY OF UNPROFESSIONAL  
29 CONDUCT OR IS OR MAY BE MENTALLY OR PHYSICALLY UNABLE SAFELY TO ENGAGE IN THE  
30 PRACTICE OF PHARMACY. ANY PERSON MAY, AND A LICENSEE OR PERMITTEE OF THE  
31 BOARD MUST, REPORT TO THE BOARD ANY INFORMATION THAT APPEARS TO SHOW THAT A  
32 PHARMACIST, PHARMACY INTERN OR GRADUATE INTERN IS OR MAY BE PROFESSIONALLY  
33 INCOMPETENT, IS OR MAY BE GUILTY OF UNPROFESSIONAL CONDUCT OR IS OR MAY BE  
34 MENTALLY OR PHYSICALLY UNABLE SAFELY TO ENGAGE IN THE PRACTICE OF PHARMACY.  
35 THE BOARD OR THE EXECUTIVE DIRECTOR SHALL NOTIFY THE PHARMACIST, PHARMACY  
36 INTERN OR GRADUATE INTERN AS TO THE CONTENT OF THE COMPLAINT AS SOON AS  
37 REASONABLE. ANY PERSON OR ENTITY THAT REPORTS OR PROVIDES INFORMATION TO THE  
38 BOARD IN GOOD FAITH IS NOT SUBJECT TO AN ACTION FOR CIVIL DAMAGES. IT IS AN  
39 ACT OF UNPROFESSIONAL CONDUCT FOR ANY PHARMACIST, PHARMACY INTERN OR GRADUATE  
40 INTERN TO FAIL TO REPORT AS REQUIRED BY THIS SECTION.

41          E. THE PHARMACY PERMITTEE OR PHARMACIST IN CHARGE OF A PHARMACY  
42 LOCATED IN THIS STATE MUST INFORM THE BOARD IF A PHARMACIST, PHARMACY INTERN  
43 OR GRADUATE INTERN EMPLOYED BY THE PHARMACY IS TERMINATED BECAUSE OF ACTIONS  
44 BY THE PHARMACIST, PHARMACY INTERN OR GRADUATE INTERN THAT APPEAR TO SHOW  
45 THAT THE PHARMACIST, PHARMACY INTERN OR GRADUATE INTERN IS OR MAY BE

1 PROFESSIONALLY INCOMPETENT, IS OR MAY BE GUILTY OF UNPROFESSIONAL CONDUCT OR  
2 IS OR MAY BE MENTALLY OR PHYSICALLY UNABLE SAFELY TO ENGAGE IN THE PRACTICE  
3 OF PHARMACY, ALONG WITH A GENERAL STATEMENT OF THE REASONS THAT LED THE  
4 PHARMACY TO TAKE THE ACTION. THE PHARMACY PERMITTEE OR PHARMACIST IN CHARGE  
5 OF A PHARMACY LOCATED IN THIS STATE MUST INFORM THE BOARD IF A PHARMACIST,  
6 PHARMACY INTERN OR GRADUATE INTERN UNDER INVESTIGATION RESIGNS OR IF A  
7 PHARMACIST, PHARMACY INTERN OR GRADUATE INTERN RESIGNS IN LIEU OF  
8 DISCIPLINARY ACTION BY THE PHARMACY. NOTIFICATION MUST INCLUDE A GENERAL  
9 STATEMENT OF THE REASONS FOR THE RESIGNATION. A PERSON WHO REPORTS  
10 INFORMATION IN GOOD FAITH PURSUANT TO THIS SUBSECTION IS NOT SUBJECT TO CIVIL  
11 LIABILITY.

12 F. THE BOARD OR, IF DELEGATED BY THE BOARD, THE EXECUTIVE DIRECTOR  
13 SHALL REQUIRE ANY COMBINATION OF MENTAL, PHYSICAL, PSYCHOLOGICAL, PSYCHIATRIC  
14 OR MEDICAL COMPETENCY EXAMINATIONS OR PHARMACIST LICENSURE EXAMINATIONS AND  
15 CONDUCT NECESSARY INVESTIGATIONS INCLUDING INVESTIGATIONAL INTERVIEWS BETWEEN  
16 REPRESENTATIVES OF THE BOARD AND THE PHARMACIST, PHARMACY INTERN OR GRADUATE  
17 INTERN TO FULLY INFORM ITSELF ABOUT ANY INFORMATION FILED WITH THE BOARD  
18 UNDER THIS SECTION. THESE EXAMINATIONS MAY ALSO INCLUDE BIOLOGICAL FLUID  
19 TESTING. THE BOARD MAY REQUIRE THE PHARMACIST, PHARMACY INTERN OR GRADUATE  
20 INTERN, AT THAT PERSON'S EXPENSE, TO UNDERGO ASSESSMENT BY A BOARD APPROVED  
21 SUBSTANCE ABUSE TREATMENT AND REHABILITATION PROGRAM.

22 G. IF AFTER COMPLETING ITS INVESTIGATION THE BOARD FINDS THAT THE  
23 INFORMATION PROVIDED PURSUANT TO THIS SECTION IS NOT OF SUFFICIENT  
24 SERIOUSNESS TO MERIT DISCIPLINARY ACTION AGAINST THE LICENSE OF THE  
25 PHARMACIST, PHARMACY INTERN OR GRADUATE INTERN, THE BOARD MAY TAKE ANY OF THE  
26 FOLLOWING ACTIONS:

- 27 1. DISMISS IF THE COMPLAINT IS WITHOUT MERIT.
- 28 2. FILE AN ADVISORY LETTER. THE LICENSEE MAY FILE A WRITTEN RESPONSE  
29 WITH THE BOARD WITHIN THIRTY DAYS AFTER RECEIVING THE ADVISORY LETTER.

30 H. THE BOARD SHALL NOT DISCLOSE THE NAME OF THE PERSON WHO PROVIDED  
31 INFORMATION REGARDING A LICENSEE'S DRUG OR ALCOHOL IMPAIRMENT OR THE NAME OF  
32 THE PERSON WHO FILES A COMPLAINT IF THAT PERSON REQUESTS ANONYMITY.

33 I. IF AFTER COMPLETING ITS INVESTIGATION THE BOARD BELIEVES THAT THE  
34 INFORMATION IS OR MAY BE TRUE, IT MAY REQUEST A CONFERENCE WITH THE  
35 PHARMACIST, PHARMACY INTERN OR GRADUATE INTERN. IF THE PHARMACIST, PHARMACY  
36 INTERN OR GRADUATE INTERN REFUSES THE INVITATION FOR CONFERENCE AND THE  
37 INVESTIGATION INDICATES THAT GROUNDS MAY EXIST FOR REVOCATION OR SUSPENSION  
38 OF A LICENSE, PROBATION, ISSUANCE OF A DECREE OF CENSURE OR A LETTER OF  
39 REPRIMAND OR IMPOSITION OF A CIVIL PENALTY, THE BOARD SHALL ISSUE A FORMAL  
40 NOTICE THAT A HEARING BE HELD PURSUANT TO TITLE 41, CHAPTER 6, ARTICLE 10.

41 J. IF THROUGH INFORMATION PROVIDED PURSUANT TO THIS SECTION OR BY  
42 OTHER MEANS, THE BOARD FINDS THAT THE PROTECTION OF THE PUBLIC HEALTH,  
43 WELFARE AND SAFETY REQUIRES EMERGENCY ACTION AGAINST THE LICENSE OF A  
44 PHARMACIST, PHARMACY INTERN OR GRADUATE INTERN, IT MAY ORDER A SUMMARY  
45 SUSPENSION OF THE LICENSE PENDING A FORMAL HEARING FOR LICENSE REVOCATION OR

1 OTHER ACTION AUTHORIZED BY THIS SECTION TO BE HELD BY THE BOARD WITHIN TEN  
2 DAYS AFTER IT ISSUES THE ORDER.

3 K. IF AFTER COMPLETING THE CONFERENCE THE BOARD FINDS THE INFORMATION  
4 PROVIDED PURSUANT TO THIS SECTION IS NOT OF SUFFICIENT SERIOUSNESS TO MERIT  
5 REVOCATION OR SUSPENSION OF A LICENSE, PROBATION, ISSUANCE OF A DECREE OF  
6 CENSURE OR A LETTER OF REPRIMAND OR IMPOSITION OF A CIVIL PENALTY, IT MAY  
7 TAKE THE FOLLOWING ACTIONS:

8 1. DISMISS IF THE INFORMATION IS WITHOUT MERIT.

9 2. FILE AN ADVISORY LETTER. THE LICENSEE MAY FILE A WRITTEN RESPONSE  
10 WITH THE BOARD WITHIN THIRTY DAYS AFTER THE LICENSEE RECEIVES THE ADVISORY  
11 LETTER.

12 L. IF DURING A CONFERENCE THE BOARD FINDS THAT THE INFORMATION  
13 PROVIDED PURSUANT TO THIS SECTION INDICATES THAT GROUNDS MAY EXIST FOR  
14 REVOCATION OR SUSPENSION OF A LICENSE, PROBATION, ISSUANCE OF A DECREE OF  
15 CENSURE OR A LETTER OF REPRIMAND OR IMPOSITION OF A CIVIL PENALTY, IT MAY  
16 TAKE THE FOLLOWING ACTIONS:

17 1. DISMISS IF THE INFORMATION IS WITHOUT MERIT.

18 2. FILE AN ADVISORY LETTER. THE LICENSEE MAY FILE A WRITTEN RESPONSE  
19 WITH THE BOARD WITHIN THIRTY DAYS AFTER THE LICENSEE RECEIVES THE ADVISORY  
20 LETTER.

21 3. ENTER INTO AN AGREEMENT WITH THE LICENSEE TO DISCIPLINE THE  
22 LICENSEE, RESTRICT THE LICENSEE'S PRACTICE OR PROFESSIONAL ACTIVITIES OR  
23 REHABILITATE, RETRAIN OR ASSESS THE LICENSEE IN ORDER TO PROTECT THE PUBLIC  
24 AND ENSURE THE LICENSEE'S ABILITY TO SAFELY ENGAGE IN THE PRACTICE OF  
25 PHARMACY. THE AGREEMENT MAY INCLUDE AT LEAST THE FOLLOWING:

26 (a) ISSUANCE OF A LETTER OF REPRIMAND.

27 (b) ISSUANCE OF A DECREE OF CENSURE.

28 (c) PRACTICE OR PROFESSIONAL RESTRICTIONS, SUCH AS NOT ACTING AS A  
29 PHARMACIST IN CHARGE OR PHARMACY INTERN PRECEPTOR OR WORKING WITH ANOTHER  
30 PHARMACIST.

31 (d) REHABILITATIVE, RETRAINING OR ASSESSMENT PROGRAMS INCLUDING:

32 (i) BOARD APPROVED COMMUNITY SERVICE.

33 (ii) SUCCESSFUL COMPLETION OF ADDITIONAL PHARMACIST CONTINUING  
34 EDUCATION HOURS.

35 (iii) SUCCESSFUL PASSAGE OF BOARD APPROVED PHARMACIST LICENSURE  
36 EXAMINATIONS.

37 (iv) SUCCESSFUL COMPLETION OF A BOARD APPROVED SUBSTANCE ABUSE  
38 TREATMENT AND REHABILITATION PROGRAM AT THE LICENSEE'S OWN EXPENSE.

39 (e) A CIVIL PENALTY NOT TO EXCEED ONE THOUSAND DOLLARS FOR EACH  
40 VIOLATION OF THIS CHAPTER OR A RULE ADOPTED UNDER THIS CHAPTER.

41 (f) A PERIOD AND TERMS OF PROBATION BEST ADAPTED TO PROTECT THE PUBLIC  
42 HEALTH AND SAFETY AND REHABILITATE OR EDUCATE THE LICENSEE CONCERNED.  
43 PROBATION MAY INCLUDE TEMPORARY SUSPENSION AND ANY OR ALL OF THE DISCIPLINARY  
44 ACTIONS, PRACTICE OR PROFESSIONAL RESTRICTIONS, REHABILITATIVE, RETRAINING OR

1 ASSESSMENT PROGRAMS LISTED IN THIS SECTION OR ANY OTHER PROGRAM AGREED TO BY  
2 THE BOARD AND THE LICENSEE.

3 M. IF THE BOARD FINDS THAT THE INFORMATION PROVIDED PURSUANT TO THIS  
4 SECTION AND ADDITIONAL INFORMATION PROVIDED DURING THE CONFERENCE WARRANTS  
5 REVOCATION OR SUSPENSION OF A LICENSE, PROBATION, ISSUANCE OF A DECREE OF  
6 CENSURE OR A LETTER OF REPRIMAND OR IMPOSITION OF A CIVIL PENALTY, IT SHALL  
7 INITIATE FORMAL PROCEEDINGS PURSUANT TO TITLE 41, CHAPTER 6, ARTICLE 10.

8 N. IF THE BOARD FINDS THAT THE INFORMATION PROVIDED PURSUANT TO THIS  
9 SECTION WARRANTS REVOCATION OR SUSPENSION OF A LICENSE, PROBATION, ISSUANCE  
10 OF A DECREE OF CENSURE OR A LETTER OF REPRIMAND OR IMPOSITION OF A CIVIL  
11 PENALTY, IT SHALL INITIATE FORMAL PROCEEDINGS PURSUANT TO TITLE 41, CHAPTER  
12 6, ARTICLE 10.

13 O. IF THE LICENSEE WISHES TO BE PRESENT AT THE FORMAL HEARING IN  
14 PERSON OR BY REPRESENTATION, OR BOTH, THE LICENSEE MUST FILE WITH THE BOARD  
15 AN ANSWER TO THE CHARGES IN THE NOTICE OF HEARING. THE ANSWER MUST BE IN  
16 WRITING, VERIFIED UNDER OATH AND FILED WITHIN THIRTY DAYS AFTER SERVICE OF  
17 THE NOTICE OF HEARING. FAILURE TO ANSWER THE BOARD'S NOTICE OF HEARING IS  
18 DEEMED AN ADMISSION OF THE CHARGES IN THE NOTICE OF HEARING.

19 P. AN ADVISORY LETTER IS A NONDISCIPLINARY PUBLIC DOCUMENT.

20 Q. IF THE BOARD DURING AN INVESTIGATION DETERMINES THAT A CRIMINAL  
21 VIOLATION MIGHT HAVE OCCURRED, IT SHALL DISCLOSE ITS INVESTIGATIVE EVIDENCE  
22 AND INFORMATION TO THE APPROPRIATE CRIMINAL JUSTICE AGENCY FOR ITS  
23 CONSIDERATION.

24 R. IN DETERMINING THE APPROPRIATE DISCIPLINARY ACTION UNDER THIS  
25 SECTION, THE BOARD SHALL CONSIDER ALL PREVIOUS NONDISCIPLINARY AND  
26 DISCIPLINARY ACTIONS AGAINST A LICENSEE.

27 S. THE BOARD MAY DENY A LICENSE TO AN APPLICANT FOR THE GROUNDS  
28 PRESCRIBED IN SUBSECTION A OF THIS SECTION.

29 T. A PERSON LICENSED PURSUANT TO THIS CHAPTER OR BY ANY OTHER  
30 JURISDICTION WHO HAS A LICENSE REVOKED OR SUSPENDED SHALL NOT OBTAIN A  
31 LICENSE AS A PHARMACY INTERN, GRADUATE INTERN, PHARMACY TECHNICIAN OR  
32 PHARMACY TECHNICIAN TRAINEE OR WORK AS A PHARMACY INTERN, GRADUATE INTERN,  
33 PHARMACY TECHNICIAN OR PHARMACY TECHNICIAN TRAINEE WITHOUT THE APPROVAL OF  
34 THE BOARD OR ITS DESIGNEE.

35 32-1927.01. Pharmacy technicians; pharmacy technician trainees;  
36 disciplinary action

37 A. A PHARMACY TECHNICIAN OR PHARMACY TECHNICIAN TRAINEE IS SUBJECT TO  
38 DISCIPLINARY ACTION BY THE BOARD FOR ANY OF THE FOLLOWING:

39 1. THE BOARD DETERMINES THAT THE LICENSEE HAS COMMITTED AN ACT OF  
40 UNPROFESSIONAL CONDUCT.

41 2. THE LICENSEE IS FOUND BY PSYCHIATRIC EXAMINATION TO BE MENTALLY  
42 UNFIT TO SAFELY PERFORM THE LICENSEE'S EMPLOYMENT DUTIES.

43 3. THE LICENSEE IS FOUND TO BE PHYSICALLY OR MENTALLY INCAPACITATED TO  
44 SUCH A DEGREE AS TO RENDER THE LICENSEE UNFIT TO SAFELY PERFORM THE  
45 LICENSEE'S EMPLOYMENT DUTIES.

1        4. THE LICENSEE IS FOUND TO BE PROFESSIONALLY INCOMPETENT TO SUCH A  
2 DEGREE AS TO RENDER THE LICENSEE UNFIT TO SAFELY PERFORM THE LICENSEE'S  
3 EMPLOYMENT DUTIES.

4        5. THE LICENSE WAS ISSUED THROUGH ERROR.

5        B. A PHARMACY TECHNICIAN OR PHARMACY TECHNICIAN TRAINEE WHO AFTER A  
6 FORMAL HEARING IS FOUND BY THE BOARD TO BE GUILTY OF UNPROFESSIONAL CONDUCT,  
7 TO BE MENTALLY OR PHYSICALLY UNABLE SAFELY TO ENGAGE IN THE PRACTICE OF  
8 PHARMACY OR TO BE PROFESSIONALLY INCOMPETENT IS SUBJECT TO ANY ONE OR  
9 COMBINATION OF THE FOLLOWING:

10        1. A CIVIL PENALTY OF NOT TO EXCEED ONE THOUSAND DOLLARS FOR EACH  
11 VIOLATION OF THIS CHAPTER OR A RULE ADOPTED UNDER THIS CHAPTER.

12        2. A LETTER OF REPRIMAND.

13        3. A DECREE OF CENSURE.

14        4. PROBATION.

15        5. SUSPENSION OR REVOCATION OF THE LICENSE.

16        C. THE BOARD MAY CHARGE THE COSTS OF FORMAL HEARINGS TO THE LICENSEE  
17 WHO IT FINDS TO BE IN VIOLATION OF THIS CHAPTER OR A RULE ADOPTED UNDER THIS  
18 CHAPTER.

19        D. THE BOARD ON ITS OWN MOTION MAY INVESTIGATE ANY EVIDENCE THAT  
20 APPEARS TO SHOW THAT A PHARMACY TECHNICIAN OR PHARMACY TECHNICIAN TRAINEE IS  
21 OR MAY BE PROFESSIONALLY INCOMPETENT, IS OR MAY BE GUILTY OF UNPROFESSIONAL  
22 CONDUCT OR IS OR MAY BE MENTALLY OR PHYSICALLY UNABLE SAFELY TO ENGAGE IN THE  
23 PERMISSIBLE ACTIVITIES OF A PHARMACY TECHNICIAN OR PHARMACY TECHNICIAN  
24 TRAINEE. ANY PERSON MAY, AND A LICENSEE OR PERMITTEE OF THE BOARD MUST,  
25 REPORT TO THE BOARD ANY INFORMATION THAT APPEARS TO SHOW THAT A PHARMACY  
26 TECHNICIAN OR PHARMACY TECHNICIAN TRAINEE IS OR MAY BE PROFESSIONALLY  
27 INCOMPETENT, IS OR MAY BE GUILTY OF UNPROFESSIONAL CONDUCT OR IS OR MAY BE  
28 MENTALLY OR PHYSICALLY UNABLE SAFELY TO ENGAGE IN THE PERMISSIBLE ACTIVITIES  
29 OF A PHARMACY TECHNICIAN OR PHARMACY TECHNICIAN TRAINEE. THE BOARD OR THE  
30 EXECUTIVE DIRECTOR SHALL NOTIFY THE PHARMACY TECHNICIAN OR PHARMACY  
31 TECHNICIAN TRAINEE AS TO THE CONTENT OF THE COMPLAINT AS SOON AS REASONABLE.  
32 ANY PERSON OR ENTITY THAT REPORTS OR PROVIDES INFORMATION TO THE BOARD IN  
33 GOOD FAITH IS NOT SUBJECT TO AN ACTION FOR CIVIL DAMAGES. IT IS AN ACT OF  
34 UNPROFESSIONAL CONDUCT FOR ANY PHARMACY TECHNICIAN OR PHARMACY TECHNICIAN  
35 TRAINEE TO FAIL TO REPORT AS REQUIRED BY THIS SECTION.

36        E. THE PHARMACY PERMITTEE OR PHARMACIST IN CHARGE OF A PHARMACY  
37 LOCATED IN THIS STATE MUST INFORM THE BOARD IF A PHARMACY TECHNICIAN OR  
38 PHARMACY TECHNICIAN TRAINEE EMPLOYED BY THE PHARMACY IS TERMINATED BECAUSE OF  
39 ACTIONS BY THAT PERSON THAT APPEAR TO SHOW THAT THE PERSON IS OR MAY BE  
40 PROFESSIONALLY INCOMPETENT, IS OR MAY BE GUILTY OF UNPROFESSIONAL CONDUCT OR  
41 IS OR MAY BE MENTALLY OR PHYSICALLY UNABLE SAFELY TO ENGAGE IN THE  
42 PERMISSIBLE ACTIVITIES OF A PHARMACY TECHNICIAN OR PHARMACY TECHNICIAN  
43 TRAINEE, ALONG WITH A GENERAL STATEMENT OF THE REASONS THAT LED THE PHARMACY  
44 TO TAKE THE ACTION. THE PHARMACY PERMITTEE OR PHARMACIST IN CHARGE OF A  
45 PHARMACY LOCATED IN THIS STATE MUST INFORM THE BOARD IF A PHARMACY TECHNICIAN

1 OR PHARMACY TECHNICIAN TRAINEE UNDER INVESTIGATION RESIGNS OR IF A PHARMACY  
2 TECHNICIAN OR PHARMACY TECHNICIAN TRAINEE RESIGNS IN LIEU OF DISCIPLINARY  
3 ACTION BY THE PHARMACY. NOTIFICATION MUST INCLUDE A GENERAL STATEMENT OF THE  
4 REASONS FOR THE RESIGNATION. A PERSON WHO REPORTS INFORMATION IN GOOD FAITH  
5 PURSUANT TO THIS SUBSECTION IS NOT SUBJECT TO CIVIL LIABILITY.

6 F. THE BOARD OR, IF DELEGATED BY THE BOARD, THE EXECUTIVE DIRECTOR  
7 SHALL REQUIRE ANY COMBINATION OF MENTAL, PHYSICAL, PSYCHOLOGICAL, PSYCHIATRIC  
8 OR MEDICAL COMPETENCY EXAMINATIONS OR PHARMACY TECHNICIAN LICENSURE  
9 EXAMINATIONS AND CONDUCT NECESSARY INVESTIGATIONS INCLUDING INVESTIGATIONAL  
10 INTERVIEWS BETWEEN REPRESENTATIVES OF THE BOARD AND THE PHARMACY TECHNICIAN  
11 OR PHARMACY TECHNICIAN TRAINEE TO FULLY INFORM ITSELF ABOUT ANY INFORMATION  
12 FILED WITH THE BOARD PURSUANT TO THIS SECTION. THESE EXAMINATIONS MAY ALSO  
13 INCLUDE BIOLOGICAL FLUID TESTING. THE BOARD MAY REQUIRE THE LICENSEE, AT  
14 THAT PERSON'S EXPENSE, TO UNDERGO ASSESSMENT BY A BOARD APPROVED SUBSTANCE  
15 ABUSE TREATMENT AND REHABILITATION PROGRAM.

16 G. IF AFTER COMPLETING ITS INVESTIGATION THE BOARD FINDS THAT THE  
17 INFORMATION PROVIDED PURSUANT TO THIS SECTION IS NOT OF SUFFICIENT  
18 SERIOUSNESS TO MERIT DISCIPLINARY ACTION AGAINST THE LICENSE OF THE PHARMACY  
19 TECHNICIAN OR PHARMACY TECHNICIAN TRAINEE, THE BOARD MAY TAKE ANY OF THE  
20 FOLLOWING ACTIONS:

21 1. DISMISS IF THE COMPLAINT IS WITHOUT MERIT.

22 2. FILE AN ADVISORY LETTER. THE LICENSEE MAY FILE A WRITTEN RESPONSE  
23 WITH THE BOARD WITHIN THIRTY DAYS AFTER RECEIVING THE ADVISORY LETTER.

24 H. THE BOARD SHALL NOT DISCLOSE THE NAME OF THE PERSON WHO PROVIDED  
25 INFORMATION REGARDING A LICENSEE'S DRUG OR ALCOHOL IMPAIRMENT OR THE NAME OF  
26 THE PERSON WHO FILES A COMPLAINT IF THAT PERSON REQUESTS ANONYMITY.

27 I. IF AFTER COMPLETING ITS INVESTIGATION THE BOARD BELIEVES THAT THE  
28 INFORMATION IS OR MAY BE TRUE, IT MAY REQUEST A CONFERENCE WITH THE LICENSEE.  
29 IF THE LICENSEE REFUSES THE INVITATION FOR CONFERENCE AND THE INVESTIGATION  
30 INDICATES THAT GROUNDS MAY EXIST FOR REVOCATION OR SUSPENSION OF A LICENSE,  
31 PROBATION, ISSUANCE OF A DECREE OF CENSURE OR A LETTER OF REPRIMAND OR  
32 IMPOSITION OF A CIVIL PENALTY, THE BOARD SHALL ISSUE A FORMAL NOTICE THAT A  
33 HEARING BE HELD PURSUANT TO TITLE 41, CHAPTER 6, ARTICLE 10.

34 J. IF THROUGH INFORMATION PROVIDED PURSUANT TO THIS SECTION OR BY  
35 OTHER MEANS, THE BOARD FINDS THAT THE PROTECTION OF THE PUBLIC HEALTH,  
36 WELFARE AND SAFETY REQUIRES EMERGENCY ACTION AGAINST THE LICENSE OF A  
37 PHARMACY TECHNICIAN OR PHARMACY TECHNICIAN TRAINEE, IT MAY ORDER A SUMMARY  
38 SUSPENSION OF THE LICENSE PENDING A FORMAL HEARING FOR LICENSE REVOCATION OR  
39 OTHER ACTION AUTHORIZED BY THIS SECTION TO BE HELD BY THE BOARD WITHIN TEN  
40 DAYS AFTER IT ISSUES THE ORDER.

41 K. IF AFTER COMPLETING THE CONFERENCE THE BOARD FINDS THE INFORMATION  
42 PROVIDED PURSUANT TO THIS SECTION IS NOT OF SUFFICIENT SERIOUSNESS TO MERIT  
43 REVOCATION OR SUSPENSION OF A LICENSE, PROBATION, ISSUANCE OF A DECREE OF  
44 CENSURE OR A LETTER OF REPRIMAND OR IMPOSITION OF A CIVIL PENALTY, IT MAY  
45 TAKE THE FOLLOWING ACTIONS:

1 1. DISMISS IF THE INFORMATION IS WITHOUT MERIT.

2 2. FILE AN ADVISORY LETTER. THE LICENSEE MAY FILE A WRITTEN RESPONSE  
3 WITH THE BOARD WITHIN THIRTY DAYS AFTER THE LICENSEE RECEIVES THE ADVISORY  
4 LETTER.

5 L. IF DURING A CONFERENCE THE BOARD FINDS THAT THE INFORMATION  
6 PROVIDED PURSUANT TO THIS SECTION INDICATES THAT GROUNDS MAY EXIST FOR  
7 REVOCATION OR SUSPENSION OF A LICENSE, PROBATION, ISSUANCE OF A DECREE OF  
8 CENSURE OR A LETTER OF REPRIMAND OR IMPOSITION OF A CIVIL PENALTY, IT MAY  
9 TAKE THE FOLLOWING ACTIONS:

10 1. DISMISS IF THE INFORMATION IS WITHOUT MERIT.

11 2. FILE AN ADVISORY LETTER. THE LICENSEE MAY FILE A WRITTEN RESPONSE  
12 WITH THE BOARD WITHIN THIRTY DAYS AFTER THE LICENSEE RECEIVES THE ADVISORY  
13 LETTER.

14 3. ENTER INTO AN AGREEMENT WITH THE LICENSEE TO DISCIPLINE THE  
15 LICENSEE, RESTRICT THE LICENSEE'S PRACTICE OR PROFESSIONAL ACTIVITIES OR  
16 REHABILITATE, RETRAIN OR ASSESS THE LICENSEE IN ORDER TO PROTECT THE PUBLIC  
17 AND ENSURE THE LICENSEE'S ABILITY TO SAFELY ENGAGE IN THE PERMISSIBLE  
18 ACTIVITIES OF A PHARMACY TECHNICIAN OR PHARMACY TECHNICIAN TRAINEE. THE  
19 AGREEMENT MAY INCLUDE AT LEAST THE FOLLOWING:

20 (a) ISSUANCE OF A LETTER OF REPRIMAND.

21 (b) ISSUANCE OF A DECREE OF CENSURE.

22 (c) PRACTICE OR PROFESSIONAL RESTRICTIONS, SUCH AS DOING THE FOLLOWING  
23 ONLY UNDER PHARMACIST SUPERVISION:

24 (i) ENTERING PRESCRIPTION OR PATIENT DATA.

25 (ii) INITIATING OR ACCEPTING VERBAL REFILL AUTHORIZATION.

26 (iii) COUNTING, POURING, PACKAGING OR LABELING PRESCRIPTION  
27 MEDICATION.

28 (iv) COMPOUNDING, RECONSTITUTING, PREPACKAGING OR REPACKAGING DRUGS.

29 (d) REHABILITATIVE, RETRAINING OR ASSESSMENT PROGRAMS INCLUDING:

30 (i) BOARD APPROVED COMMUNITY SERVICE.

31 (ii) SUCCESSFUL COMPLETION OF ADDITIONAL PHARMACY CONTINUING EDUCATION  
32 HOURS.

33 (iii) SUCCESSFUL PASSAGE OF BOARD APPROVED PHARMACIST TECHNICIAN  
34 LICENSURE EXAMINATIONS.

35 (iv) SUCCESSFUL COMPLETION OF A BOARD APPROVED SUBSTANCE ABUSE  
36 TREATMENT AND REHABILITATION PROGRAM AT THE LICENSEE'S OWN EXPENSE.

37 (e) A CIVIL PENALTY NOT TO EXCEED ONE THOUSAND DOLLARS FOR EACH  
38 VIOLATION OF THIS CHAPTER OR A RULE ADOPTED UNDER THIS CHAPTER.

39 (f) A PERIOD AND TERMS OF PROBATION BEST ADAPTED TO PROTECT THE PUBLIC  
40 HEALTH AND SAFETY AND REHABILITATE OR EDUCATE THE LICENSEE CONCERNED.  
41 PROBATION MAY INCLUDE TEMPORARY SUSPENSION AND ANY OR ALL OF THE DISCIPLINARY  
42 ACTIONS, PRACTICE OR PROFESSIONAL RESTRICTIONS, REHABILITATIVE, RETRAINING OR  
43 ASSESSMENT PROGRAMS LISTED IN THIS SECTION OR ANY OTHER PROGRAM AGREED TO BY  
44 THE BOARD AND THE LICENSEE.

1 M. IF THE BOARD FINDS THAT THE INFORMATION PROVIDED PURSUANT TO THIS  
2 SECTION AND ADDITIONAL INFORMATION PROVIDED DURING THE CONFERENCE WARRANTS  
3 REVOCATION OR SUSPENSION OF A LICENSE, PROBATION, ISSUANCE OF A DECREE OF  
4 CENSURE OR A LETTER OF REPRIMAND OR IMPOSITION OF A CIVIL PENALTY, IT SHALL  
5 INITIATE FORMAL PROCEEDINGS PURSUANT TO TITLE 41, CHAPTER 6, ARTICLE 10.

6 N. IF THE BOARD FINDS THAT THE INFORMATION PROVIDED PURSUANT TO THIS  
7 SECTION WARRANTS REVOCATION OR SUSPENSION OF A LICENSE, PROBATION, ISSUANCE  
8 OF A DECREE OF CENSURE OR A LETTER OF REPRIMAND OR IMPOSITION OF A CIVIL  
9 PENALTY, IT SHALL INITIATE FORMAL PROCEEDINGS PURSUANT TO TITLE 41, CHAPTER  
10 6, ARTICLE 10.

11 O. IF THE LICENSEE WISHES TO BE PRESENT AT THE FORMAL HEARING IN  
12 PERSON OR BY REPRESENTATION, OR BOTH, THE LICENSEE MUST FILE WITH THE BOARD  
13 AN ANSWER TO THE CHARGES IN THE NOTICE OF HEARING. THE ANSWER MUST BE IN  
14 WRITING, VERIFIED UNDER OATH AND FILED WITHIN THIRTY DAYS AFTER SERVICE OF  
15 THE NOTICE OF HEARING. FAILURE TO ANSWER THE BOARD'S NOTICE OF HEARING IS  
16 DEEMED AN ADMISSION OF THE CHARGES IN THE NOTICE OF HEARING.

17 P. AN ADVISORY LETTER IS A NONDISCIPLINARY PUBLIC DOCUMENT.

18 Q. IF THE BOARD DURING AN INVESTIGATION DETERMINES THAT A CRIMINAL  
19 VIOLATION MIGHT HAVE OCCURRED, IT SHALL DISCLOSE ITS INVESTIGATIVE EVIDENCE  
20 AND INFORMATION TO THE APPROPRIATE CRIMINAL JUSTICE AGENCY FOR ITS  
21 CONSIDERATION.

22 R. IN DETERMINING THE APPROPRIATE DISCIPLINARY ACTION UNDER THIS  
23 SECTION, THE BOARD SHALL CONSIDER ALL PREVIOUS NONDISCIPLINARY AND  
24 DISCIPLINARY ACTIONS AGAINST A LICENSEE.

25 S. THE BOARD MAY DENY A LICENSE TO AN APPLICANT FOR THE GROUNDS  
26 PRESCRIBED IN SUBSECTION A OF THIS SECTION.

27 T. A PERSON LICENSED PURSUANT TO THIS CHAPTER OR BY ANY OTHER  
28 JURISDICTION WHO HAS A LICENSE REVOKED OR SUSPENDED SHALL NOT OBTAIN A  
29 LICENSE AS A PHARMACY TECHNICIAN OR PHARMACY TECHNICIAN TRAINEE OR WORK AS A  
30 PHARMACY TECHNICIAN OR PHARMACY TECHNICIAN TRAINEE WITHOUT THE APPROVAL OF  
31 THE BOARD OR ITS DESIGNEE.

32 32-1927.02. Permittees; disciplinary action

33 A. THE BOARD MAY DISCIPLINE A PERMITTEE IF:

34 1. THE BOARD DETERMINES THAT THE PERMITTEE OR PERMITTEE'S EMPLOYEE IS  
35 GUILTY OF UNETHICAL CONDUCT PURSUANT TO SECTION 32-1901.01, SUBSECTION A.

36 2. PURSUANT TO A PSYCHIATRIC EXAMINATION, THE PERMITTEE OR THE  
37 PERMITTEE'S EMPLOYEE IS FOUND TO BE MENTALLY UNFIT TO SAFELY ENGAGE IN  
38 EMPLOYMENT DUTIES.

39 3. THE BOARD DETERMINES THAT THE PERMITTEE OR THE PERMITTEE'S EMPLOYEE  
40 IS PHYSICALLY OR MENTALLY INCAPACITATED TO SUCH A DEGREE AS TO RENDER THE  
41 PERMITTEE OR PERMITTEE'S EMPLOYEE UNFIT TO SAFELY ENGAGE IN EMPLOYMENT  
42 DUTIES.

43 4. THE PERMIT WAS ISSUED THROUGH ERROR.



1           5. A PERMITTEE OR PERMITTEE'S EMPLOYEE ALLOWS A PERSON WHO DOES NOT  
2 POSSESS A CURRENT LICENSE ISSUED BY THE BOARD TO WORK AS A PHARMACIST,  
3 PHARMACY INTERN, GRADUATE INTERN, PHARMACY TECHNICIAN OR PHARMACY TECHNICIAN  
4 TRAINEE.

5           B. A PERMITTEE WHO AFTER A FORMAL HEARING IS FOUND BY THE BOARD TO BE  
6 GUILTY OF UNETHICAL CONDUCT, TO BE MENTALLY OR PHYSICALLY UNABLE SAFELY TO  
7 ENGAGE IN EMPLOYMENT DUTIES OR TO BE IN VIOLATION OF THIS CHAPTER OR A RULE  
8 ADOPTED UNDER THIS CHAPTER OR WHOSE EMPLOYEE AFTER A FORMAL HEARING IS FOUND  
9 BY THE BOARD TO BE GUILTY OF UNETHICAL CONDUCT, TO BE MENTALLY OR PHYSICALLY  
10 UNABLE SAFELY TO ENGAGE IN EMPLOYMENT DUTIES OR TO BE IN VIOLATION OF THIS  
11 CHAPTER OR A RULE ADOPTED UNDER THIS CHAPTER IS SUBJECT TO ANY ONE OR  
12 COMBINATION OF THE FOLLOWING:

13           1. A CIVIL PENALTY NOT TO EXCEED ONE THOUSAND DOLLARS FOR EACH  
14 VIOLATION OF THIS CHAPTER OR A RULE ADOPTED UNDER THIS CHAPTER.

15           2. A LETTER OF REPRIMAND.

16           3. A DECREE OF CENSURE.

17           4. PROBATION.

18           5. SUSPENSION OR REVOCATION OF THE PERMIT.

19           C. THE BOARD MAY CHARGE THE COSTS OF FORMAL HEARINGS TO THE PERMITTEE  
20 WHO IT FINDS TO BE IN VIOLATION OF THIS CHAPTER OR A RULE ADOPTED UNDER THIS  
21 CHAPTER OR WHOSE EMPLOYEE IT FINDS TO BE IN VIOLATION OF THIS CHAPTER OR A  
22 RULE ADOPTED UNDER THIS CHAPTER.

23           D. THE BOARD OF ITS OWN MOTION MAY INVESTIGATE ANY EVIDENCE THAT  
24 APPEARS TO SHOW THAT A PERMITTEE OR PERMITTEE'S EMPLOYEE IS OR MAY BE GUILTY  
25 OF UNETHICAL CONDUCT, IS OR MAY BE MENTALLY OR PHYSICALLY UNABLE SAFELY TO  
26 ENGAGE IN EMPLOYMENT DUTIES OR IS OR MAY BE IN VIOLATION OF THIS CHAPTER OR A  
27 RULE ADOPTED UNDER THIS CHAPTER. ANY PERSON MAY, AND ANY LICENSEE OR  
28 PERMITTEE MUST, REPORT TO THE BOARD ANY INFORMATION THAT APPEARS TO SHOW THAT  
29 A PERMITTEE OR PERMITTEE'S EMPLOYEE IS OR MAY BE GUILTY OF UNETHICAL CONDUCT,  
30 IS OR MAY BE MENTALLY OR PHYSICALLY UNABLE SAFELY TO ENGAGE IN EMPLOYMENT  
31 DUTIES OR IS OR MAY BE IN VIOLATION OF THIS CHAPTER OR A RULE ADOPTED UNDER  
32 THIS CHAPTER. THE BOARD OR THE EXECUTIVE DIRECTOR SHALL NOTIFY THE PERMITTEE  
33 AS TO THE CONTENT OF THE COMPLAINT AS SOON AS REASONABLE. ANY PERSON OR  
34 ENTITY THAT REPORTS OR PROVIDES INFORMATION TO THE BOARD IN GOOD FAITH IS NOT  
35 SUBJECT TO AN ACTION FOR CIVIL DAMAGES. IT IS AN ACT OF UNETHICAL CONDUCT  
36 FOR ANY PERMITTEE TO FAIL TO REPORT AS REQUIRED BY THIS SECTION.

37           E. THE BOARD OR, IF DELEGATED BY THE BOARD, THE EXECUTIVE DIRECTOR  
38 SHALL REQUIRE ANY COMBINATION OF MENTAL, PHYSICAL, PSYCHOLOGICAL, PSYCHIATRIC  
39 OR MEDICAL COMPETENCY EXAMINATIONS AND CONDUCT NECESSARY INVESTIGATIONS  
40 INCLUDING INVESTIGATIONAL INTERVIEWS BETWEEN REPRESENTATIVES OF THE BOARD AND  
41 THE PERMITTEE OR PERMITTEE'S EMPLOYEE TO FULLY INFORM ITSELF ABOUT ANY  
42 INFORMATION FILED WITH THE BOARD UNDER SUBSECTION D OF THIS SECTION. THESE  
43 EXAMINATIONS MAY ALSO INCLUDE BIOLOGICAL FLUID TESTING. THE BOARD MAY  
44 REQUIRE THE PERMITTEE OR PERMITTEE'S EMPLOYEE, AT THAT PERSON'S EXPENSE, TO

1 UNDERGO ASSESSMENT BY A BOARD APPROVED SUBSTANCE ABUSE TREATMENT AND  
2 REHABILITATION PROGRAM.

3 F. IF AFTER COMPLETING ITS INVESTIGATION THE BOARD FINDS THAT THE  
4 INFORMATION PROVIDED PURSUANT TO SUBSECTION D OF THIS SECTION IS NOT OF  
5 SUFFICIENT SERIOUSNESS TO MERIT DISCIPLINARY ACTION AGAINST THE PERMIT, THE  
6 BOARD MAY TAKE ANY OF THE FOLLOWING ACTIONS:

7 1. DISMISS IF THE COMPLAINT IS WITHOUT MERIT.

8 2. FILE AN ADVISORY LETTER. THE PERMITTEE MAY FILE A WRITTEN RESPONSE  
9 WITH THE BOARD WITHIN THIRTY DAYS AFTER RECEIVING THE ADVISORY LETTER.

10 G. THE BOARD SHALL NOT DISCLOSE THE NAME OF THE PERSON WHO PROVIDED  
11 INFORMATION REGARDING A PERMITTEE'S OR PERMITTEE'S EMPLOYEE'S DRUG OR ALCOHOL  
12 IMPAIRMENT OR THE NAME OF THE PERSON WHO FILES A COMPLAINT IF THAT PERSON  
13 REQUESTS ANONYMITY.

14 H. IF AFTER COMPLETING ITS INVESTIGATION THE BOARD BELIEVES THAT THE  
15 INFORMATION IS OR MAY BE TRUE, IT MAY REQUEST A CONFERENCE WITH THE PERMITTEE  
16 OR PERMITTEE'S EMPLOYEE. IF THE PERMITTEE OR PERMITTEE'S EMPLOYEE REFUSES  
17 THE INVITATION FOR CONFERENCE AND THE INVESTIGATION INDICATES THAT GROUNDS  
18 MAY EXIST FOR REVOCATION OR SUSPENSION OF A LICENSE, PROBATION, ISSUANCE OF A  
19 DECREE OF CENSURE OR A LETTER OF REPRIMAND OR IMPOSITION OF A CIVIL PENALTY,  
20 THE BOARD SHALL ISSUE A FORMAL NOTICE THAT A HEARING BE HELD PURSUANT TO  
21 TITLE 41, CHAPTER 6, ARTICLE 10.

22 I. IF THROUGH INFORMATION PROVIDED PURSUANT TO SUBSECTION D OF THIS  
23 SECTION OR BY OTHER MEANS THE BOARD FINDS THAT THE PROTECTION OF THE PUBLIC  
24 HEALTH, WELFARE AND SAFETY REQUIRES EMERGENCY ACTION AGAINST THE PERMIT, IT  
25 MAY ORDER A SUMMARY SUSPENSION OF THE PERMIT PENDING A FORMAL HEARING FOR  
26 PERMIT REVOCATION OR OTHER ACTION AUTHORIZED BY THIS SECTION TO BE HELD BY  
27 THE BOARD WITHIN TEN DAYS AFTER THE BOARD ISSUES THE ORDER.

28 J. IF AFTER COMPLETING THE CONFERENCE THE BOARD FINDS THE INFORMATION  
29 PROVIDED PURSUANT TO SUBSECTION D OF THIS SECTION IS NOT OF SUFFICIENT  
30 SERIOUSNESS TO MERIT REVOCATION OR SUSPENSION OF A LICENSE, PROBATION,  
31 ISSUANCE OF A DECREE OF CENSURE OR A LETTER OF REPRIMAND OR IMPOSITION OF A  
32 CIVIL PENALTY, IT MAY TAKE THE FOLLOWING ACTIONS:

33 1. DISMISS IF THE INFORMATION IS WITHOUT MERIT.

34 2. FILE AN ADVISORY LETTER. THE PERMITTEE MAY FILE A WRITTEN RESPONSE  
35 WITH THE BOARD WITHIN THIRTY DAYS AFTER RECEIVING THE ADVISORY LETTER.

36 K. IF DURING A CONFERENCE THE BOARD FINDS THAT THE INFORMATION  
37 PROVIDED PURSUANT TO SUBSECTION D OF THIS SECTION INDICATES THAT GROUNDS MAY  
38 EXIST FOR REVOCATION OR SUSPENSION OF A LICENSE, PROBATION, ISSUANCE OF A  
39 DECREE OF CENSURE OR A LETTER OF REPRIMAND OR IMPOSITION OF A CIVIL PENALTY,  
40 IT MAY TAKE THE FOLLOWING ACTIONS:

41 1. DISMISS IF THE INFORMATION IS WITHOUT MERIT.

42 2. FILE AN ADVISORY LETTER. THE PERMITTEE MAY FILE A WRITTEN RESPONSE  
43 WITH THE BOARD WITHIN THIRTY DAYS AFTER THE PERMITTEE RECEIVES THE ADVISORY  
44 LETTER.

3. ENTER INTO AN AGREEMENT WITH THE PERMITTEE TO DISCIPLINE THE PERMITTEE, RESTRICT THE PERMITTEE'S BUSINESS ACTIVITIES OR REHABILITATE OR ASSESS THE PERMITTEE IN ORDER TO PROTECT THE PUBLIC AND ENSURE THE PERMITTEE'S ABILITY TO SAFELY ENGAGE IN EMPLOYMENT DUTIES. THE AGREEMENT MAY INCLUDE, AT A MINIMUM, THE FOLLOWING DISCIPLINARY ACTIONS, BUSINESS ACTIVITY RESTRICTIONS AND REHABILITATIVE OR ASSESSMENT PROGRAMS:

(a) ISSUANCE OF A LETTER OF REPRIMAND.

(b) ISSUANCE OF A DECREE OF CENSURE.

(c) BUSINESS ACTIVITY RESTRICTIONS INCLUDING LIMITATIONS ON THE NUMBER, TYPE, CLASSIFICATION OR SCHEDULE OF DRUG, DEVICE, POISON, HAZARDOUS SUBSTANCE, CONTROLLED SUBSTANCE OR PRECURSOR CHEMICAL THAT MAY BE MANUFACTURED, SOLD, DISTRIBUTED OR DISPENSED.

(d) REHABILITATIVE OR ASSESSMENT PROGRAMS, INCLUDING BOARD APPROVED COMMUNITY SERVICE OR SUCCESSFUL COMPLETION OF A BOARD APPROVED SUBSTANCE ABUSE TREATMENT AND REHABILITATION PROGRAM AT THE PERMITTEE'S OWN EXPENSE.

(e) A CIVIL PENALTY NOT TO EXCEED ONE THOUSAND DOLLARS FOR EACH VIOLATION OF THIS CHAPTER OR A RULE ADOPTED UNDER THIS CHAPTER.

(f) A PERIOD AND TERMS OF PROBATION BEST ADAPTED TO PROTECT THE PUBLIC HEALTH AND SAFETY AND REHABILITATE OR ASSESS THE PERMITTEE CONCERNED. PROBATION MAY INCLUDE TEMPORARY SUSPENSION AND ANY OR ALL OF THE DISCIPLINARY ACTIONS, BUSINESS PRACTICE RESTRICTIONS, REHABILITATIVE OR ASSESSMENT PROGRAMS LISTED IN THIS SECTION OR ANY OTHER PROGRAM AGREED TO BY THE BOARD AND THE PERMITTEE.

L. IF THE BOARD FINDS THAT THE INFORMATION PROVIDED PURSUANT TO SUBSECTION D OF THIS SECTION AND ADDITIONAL INFORMATION PROVIDED DURING THE CONFERENCE INDICATES THAT GROUNDS MAY EXIST FOR REVOCATION OR SUSPENSION OF A LICENSE, PROBATION, ISSUANCE OF A DECREE OF CENSURE OR A LETTER OF REPRIMAND OR IMPOSITION OF A CIVIL PENALTY, IT SHALL INITIATE FORMAL PROCEEDINGS PURSUANT TO TITLE 41, CHAPTER 6, ARTICLE 10.

M. IF THE BOARD FINDS THAT THE INFORMATION PROVIDED PURSUANT TO SUBSECTION D OF THIS SECTION WARRANTS REVOCATION OR SUSPENSION OF A LICENSE, PROBATION, ISSUANCE OF A DECREE OF CENSURE OR A LETTER OF REPRIMAND OR IMPOSITION OF A CIVIL PENALTY, IT SHALL INITIATE FORMAL PROCEEDINGS PURSUANT TO TITLE 41, CHAPTER 6, ARTICLE 10.

N. IF THE PERMITTEE WISHES TO BE PRESENT AT THE FORMAL HEARING IN PERSON OR BY REPRESENTATION, OR BOTH, THE PERMITTEE MUST FILE WITH THE BOARD AN ANSWER TO THE CHARGES IN THE NOTICE OF HEARING. THE ANSWER MUST BE IN WRITING, VERIFIED UNDER OATH AND FILED WITHIN THIRTY DAYS AFTER SERVICE OF THE NOTICE OF HEARING. FAILURE TO ANSWER THE BOARD'S NOTICE OF HEARING IS DEEMED AN ADMISSION OF THE CHARGES IN THE NOTICE OF HEARING.

O. IF THE BOARD, DURING ANY INVESTIGATION, DETERMINES THAT A CRIMINAL VIOLATION MIGHT HAVE OCCURRED, IT SHALL DISCLOSE ITS INVESTIGATIVE EVIDENCE AND INFORMATION TO THE APPROPRIATE CRIMINAL JUSTICE AGENCY FOR ITS CONSIDERATION.

1 P. IN DETERMINING THE APPROPRIATE DISCIPLINARY ACTION UNDER THIS  
2 SECTION, THE BOARD SHALL CONSIDER ALL PREVIOUS NONDISCIPLINARY AND  
3 DISCIPLINARY ACTIONS AGAINST A PERMITTEE.

4 Q. THE BOARD MAY DENY A PERMIT TO AN APPLICANT FOR THE GROUNDS  
5 PRESCRIBED IN SUBSECTION A OF THIS SECTION.

6 Sec. 9. Section 32-1932.01, Arizona Revised Statutes, is amended to  
7 read:

8 32-1932.01. Substance abuse treatment and rehabilitation  
9 program; private contract; funding

10 A. The board may establish a program for the treatment and  
11 rehabilitation of licensees who are impaired by alcohol or drug abuse. This  
12 program shall include education, intervention, therapeutic treatment and  
13 posttreatment monitoring and support.

14 B. The board may contract with other organizations to operate the  
15 program established pursuant to subsection A of this section. A contract  
16 with a private organization shall include the following requirements:

17 1. Periodic reports to the board regarding treatment program activity.

18 2. PURSUANT TO A WRITTEN REQUEST BY THE BOARD OR ITS EXECUTIVE  
19 DIRECTOR, ~~release to the board on motion and written request~~ of all treatment  
20 records.

21 3. Quarterly reports to the board, by case number, regarding each  
22 participant's diagnosis, prognosis and recommendations for continuing care,  
23 treatment and supervision.

24 4. Immediate reporting to the board of the name of an impaired  
25 licensee who the treating organization believes to be a danger to self or  
26 others.

27 5. Reports to the board, as soon as possible, of the name of a  
28 participant who refuses to submit to treatment or whose impairment is not  
29 substantially alleviated through treatment.

30 C. The board may allocate an amount of not to exceed twenty dollars  
31 from each fee it collects from biennial renewal licenses pursuant to section  
32 32-1925 for the operation of the program established by this section.

33 D. A licensee who is impaired by alcohol or drug abuse may enter into  
34 a stipulation order with the board, or the licensee may be placed on  
35 probation or be subject to other action as provided by law.

36 Sec. 10. Section 32-1940, Arizona Revised Statutes, is amended to  
37 read:

38 32-1940. Investigations; hearings; conferences; records;  
39 confidentiality

40 A. Information received and records kept by the board in connection  
41 with investigations conducted pursuant to this chapter ~~prior to~~ BEFORE a  
42 public hearing OR CONFERENCE are confidential and are not open to the public  
43 or subject to civil discovery.

1 B. Notwithstanding any other law or code of ethics regarding  
2 practitioner confidences, the physician-patient privilege between a medical  
3 practitioner and a patient, both as it relates to the competency of the  
4 witness and to the exclusion of confidential communications, ~~shall~~ DOES not  
5 pertain to any board investigations or other proceedings conducted pursuant  
6 to this chapter to the extent necessary to determine if a violation of this  
7 chapter has occurred. Communications or records disclosed pursuant to this  
8 subsection are confidential and may be used only in a judicial or  
9 administrative proceeding or investigation resulting from a report,  
10 investigation or hearing required or authorized under this chapter.

11 C. The board, its employees and agents and any other person receiving  
12 this information shall keep the identity of the patient confidential at all  
13 times.

14 D. The board shall report evidence of a crime uncovered during an  
15 investigation to the appropriate criminal justice agency.

16 E. ~~Nothing in~~ This section prevents DOES NOT PREVENT the board from  
17 disclosing investigative materials concerning a licensee's alleged violation  
18 of this chapter to the licensee or ~~his~~ THE LICENSEE'S attorney.

19 Sec. 11. Section 32-1968, Arizona Revised Statutes, is amended to  
20 read:

21 32-1968. Dispensing prescription-only drug; prescription  
22 orders; refills; labels; misbranding; dispensing  
23 soft contact lenses

24 A. A prescription-only drug shall be dispensed only under one of the  
25 following conditions:

26 1. By a medical practitioner in conformance with section 32-1921.

27 2. On a written prescription order BEARING THE PRESCRIBING MEDICAL  
28 PRACTITIONER'S MANUAL SIGNATURE.

29 3. ON AN ELECTRONICALLY TRANSMITTED PRESCRIPTION ORDER CONTAINING THE  
30 PRESCRIBING MEDICAL PRACTITIONER'S ELECTRONIC OR DIGITAL SIGNATURE THAT IS  
31 REDUCED PROMPTLY TO WRITING AND FILED BY THE PHARMACIST.

32 4. ON A WRITTEN PRESCRIPTION ORDER GENERATED FROM ELECTRONIC MEDIA  
33 CONTAINING THE PRESCRIBING MEDICAL PRACTITIONER'S ELECTRONIC OR MANUAL  
34 SIGNATURE. A PRESCRIPTION ORDER THAT CONTAINS ONLY AN ELECTRONIC SIGNATURE  
35 MUST BE APPLIED TO PAPER THAT USES SECURITY FEATURES THAT WILL ENSURE THE  
36 PRESCRIPTION ORDER IS NOT SUBJECT TO ANY FORM OF COPYING OR ALTERNATION.

37 ~~3.~~ 5. On an oral prescription order that is reduced promptly to  
38 writing and filed by the pharmacist.

39 ~~4.~~ 6. By ~~renewing~~ REFILLING any written, ELECTRONICALLY TRANSMITTED  
40 or oral prescription order if a ~~renewal~~ REFILL is authorized by the  
41 prescriber either in the original prescription order, BY AN ELECTRONICALLY  
42 TRANSMITTED REFILL ORDER THAT IS DOCUMENTED PROMPTLY AND FILED BY THE  
43 PHARMACIST or by an oral REFILL order that is ~~reduced~~ DOCUMENTED promptly ~~to~~  
44 writing and filed by the pharmacist.

B. A prescription order shall not be renewed REFILLED if it is either:

1. Ordered by the prescriber not to be renewed REFILLED.
2. More than one year since it was originally ordered.

C. A prescription order shall contain the date it was issued, the name and address of the person for whom or owner of the animal for which the drug is ordered, REFILLS AUTHORIZED, IF ANY, THE LEGIBLY PRINTED NAME, ADDRESS AND TELEPHONE NUMBER OF THE PRESCRIBING MEDICAL PRACTITIONER, the name, strength, dosage form and quantity of the drug ordered and directions for its use. ~~A written prescription order shall contain the printed name of the prescriber.~~

D. Any drug dispensed in accordance with subsection A of this section is exempt from the requirements of section 32-1967, except subsection A, paragraphs 1, 10 and 11 and the packaging requirements of subsection A, paragraphs 7 and 8, if the drug container bears a label containing the name and address of the dispenser, serial number, date of dispensing, name of the prescriber, name of the patient, or, if an animal, the name of the owner of the animal and the species of the animal, directions for use and cautionary statements, if any, contained in the order. This exemption does not apply to any drug dispensed in the course of the conduct of a business of dispensing drugs pursuant to diagnosis by mail or the internet or to a drug dispensed in violation of subsection A of this section.

E. The board may also by rule require additional information on the label of prescription medication that the board believes to be necessary for the best interest of the public's health and welfare.

F. A prescription-only drug or a controlled substance that requires a prescription order is deemed to be misbranded if, at any time before dispensing, its label fails to bear the statement "Rx only". A drug to which subsection A of this section does not apply is deemed to be misbranded if, at any time before dispensing, its label bears the caution statement quoted in this subsection.

G. A pharmacist may fill a prescription order for soft contact lenses only as provided in this chapter.

Sec. 12. Section 36-2513, Arizona Revised Statutes, is amended to read:

36-2513. Substances in schedule II

A. The following controlled substances are, unless specifically excepted, included in schedule II:

1. Any of the following substances, whether produced directly or indirectly by extraction from substances of vegetable origin or independently by means of chemical synthesis or by combination of extraction and chemical synthesis:

(a) Opium and opiate and any salt, compound, derivative or preparation of opium or opiate, excluding apomorphine, dextrorphan, nalbuphine, naloxone and naltrexone and their respective salts, but including the following:

- 1 (i) Raw opium.
- 2 (ii) Opium extracts.
- 3 (iii) Opium fluid extracts.
- 4 (iv) Powdered opium.
- 5 (v) Granulated opium.
- 6 (vi) Tincture of opium.
- 7 (vii) Codeine.
- 8 (viii) Ethylmorphine.
- 9 (ix) Etorphine hydrochloride.
- 10 (x) Hydrocodone.
- 11 (xi) Hydromorphone.
- 12 (xii) Metopon.
- 13 (xiii) Morphine.
- 14 (xiv) Oxycodone.
- 15 (xv) Oxymorphone.
- 16 (xvi) Thebaine.
- 17 (xvii) Levo-alphaacetylmethadol.
- 18 (b) Any salt, compound, derivative or preparation thereof which is
- 19 chemically equivalent or identical with any of the substances referred to in
- 20 subdivision (a) of this paragraph, except that these substances shall not
- 21 include the isoquinoline alkaloids of opium.
- 22 (c) Opium poppy and poppy straw.
- 23 (d) Coca leaves and any salt, compound, derivative or preparation of
- 24 coca leaves, including cocaine and its optical isomers and any salt,
- 25 compound, derivative or preparation thereof which is chemically equivalent or
- 26 identical with any of these substances, except that the substances shall not
- 27 include decocainized coca leaves or extraction of coca leaves, which
- 28 extractions do not contain cocaine or ecgonine.
- 29 (e) Concentrate of poppy straw (the crude extract of poppy straw in
- 30 either liquid, solid or powder form which contains the phenanthrine alkaloids
- 31 of the opium poppy).
- 32 2. Any of the following, including opiates and isomers, esters,
- 33 ethers, salts and salts of isomers of the following, whenever the existence
- 34 of these isomers, esters, ethers and salts is possible within the specific
- 35 chemical designation, dextrorphan excepted:
- 36 (a) Alfentanil.
- 37 (b) Alphaprodine.
- 38 (c) Anileridine.
- 39 (d) Bezitramide.
- 40 (e) Carfentanil.
- 41 (f) Dihydrocodeine.
- 42 (g) Diphenoxylate.
- 43 (h) Fentanyl.
- 44 (i) Isomethadone.
- 45 (j) Levomethorphan.

- 1 (k) Levorphanol.
- 2 (l) Metazocine.
- 3 (m) Methadone.
- 4 (n) Methadone--intermediate, 4-cyano-2-dimethylamino-4,  
5 4-diphenylbutane.
- 6 (o) Moramide--intermediate, 2-methyl-3-morpholino-1,  
7 1-diphenylpropane-carboxylic acid.
- 8 (p) Nabilone.
- 9 (q) Pethidine (MEPERIDINE).
- 10 (r) Pethidine--intermediate--A, 4-cyano-1-methyl-  
11 4-phenylpiperidine.
- 12 (s) Pethidine--intermediate--B, ethyl-4-phenylpiperidine-  
13 4-carboxylate.
- 14 (t) Pethidine--intermediate--C, 1-methyl-4-phenylpiperidine-  
15 4-carboxylic acid.
- 16 (u) Phenazocine.
- 17 (v) Phenylacetone.
- 18 (w) 1-(2-phenylethyl)-4-phenyl-4-acetyloxypiperidine (pepap),  
19 including its optical isomers, salts and salts of isomers.
- 20 (x) Piminodine.
- 21 (y) Racemethorphan.
- 22 (z) Racemorphan.
- 23 (aa) Sufentanil.
- 24 (bb) Remifentanil.
- 25 3. Any material, compound, mixture or preparation which contains any  
26 quantity of the following substances having a potential for abuse associated  
27 with a stimulant effect on the central nervous system:  
28 (a) Amphetamine and its salts, optical isomers and salts of its  
29 optical isomers.
- 30 (b) Methamphetamine, including its salts, isomers and salts of  
31 isomers.
- 32 (c) Phenmetrazine and its salts.
- 33 (d) Methylphenidate.
- 34 4. Any material, compound, mixture or preparation which contains any  
35 quantity of the following substances having a potential for abuse associated  
36 with a depressant effect on the central nervous system, including its salts,  
37 isomers and salts of isomers whenever the existence of such salts, isomers  
38 and salts of isomers is possible within the specific chemical designation:  
39 (a) Amobarbital.
- 40 (b) Glutethimide.
- 41 (c) Pentobarbital.
- 42 (d) Phencyclidine.
- 43 (e) Phencyclidine immediate precursors:
- 44 (i) 1-phenylcyclohexylamine.
- 45 (ii) 1-piperidinocyclohexanecarbonitrile (PCC).



(f) Secobarbital.

B. The board may except by rule any compound, mixture or preparation containing any substance listed in this section from the application of all or any part of this chapter if the compound, mixture or preparation contains one or more active medicinal ingredients and if the admixtures are included therein in combinations, quantity, proportion or concentration that vitiates the potential for abuse.

Sec. 13. Section 36-2523, Arizona Revised Statutes, is amended to read:

36-2523. Records of registrants; inspection; confidentiality

A. Persons registered to manufacture, distribute or dispense controlled substances under this chapter shall keep records and maintain inventories in conformance with the record keeping and inventory requirements of federal law and title 32, chapter 18, and with any additional rules the board issues. PRESCRIPTION ORDERS MUST BE FILED AS REQUIRED BY SECTION 36-2525.

B. A person who holds a permit to operate a pharmacy issued under title 32, chapter 18 shall inventory schedule II, III, IV and V controlled substances as prescribed by federal law. The permit holder shall conduct this inventory on May 1 of each year or as directed by the Arizona state board of pharmacy. The permit holder shall also conduct this inventory if there is a change of ownership or discontinuance of business or within ten days of a change of a pharmacist in charge.

C. These records and inventories shall be open for inspection by peace officers in the performance of their duties. An officer shall not divulge information obtained pursuant to this subsection except in connection with a prosecution, investigation, judicial proceeding or administrative proceeding in which the person to whom the information relates is a party.

Sec. 14. Section 36-2525, Arizona Revised Statutes, is amended to read:

36-2525. Prescription orders; labels

A. In addition to requirements in section 32-1968, pertaining to prescription orders for prescription-only drugs, the prescription order for a controlled substance shall bear the name, address and federal registration number of the prescriber. ~~Prescription orders for controlled substances shall be filed and records kept in conformity with the requirements of section 36-2523.~~ A prescription order for a SCHEDULE II controlled substance drug other than a hospital drug order for a hospital inpatient shall contain only one drug order per prescription blank. IF AUTHORIZED VERBALLY BY THE PRESCRIBER, THE PHARMACIST MAY MAKE CHANGES TO CORRECT ERRORS OR OMISSIONS MADE BY THE PRESCRIBER ON THE FOLLOWING PARTS OF A WRITTEN SCHEDULE II CONTROLLED SUBSTANCE PRESCRIPTION ORDER:

1. THE DATE ISSUED.
2. THE STRENGTH, DOSAGE FORM OR QUANTITY OF DRUG.
3. THE DIRECTIONS FOR ITS USE.

1           B. THE PHARMACIST MUST DOCUMENT ON THE ORIGINAL PRESCRIPTION ORDER THE  
2 CHANGES THAT WERE MADE PURSUANT TO THE VERBAL AUTHORIZATION AND RECORD THE  
3 TIME AND DATE THE AUTHORIZATION WAS GRANTED.

4           C. A PERSON REGISTERED TO DISPENSE CONTROLLED SUBSTANCES UNDER THIS  
5 CHAPTER MUST KEEP AND MAINTAIN PRESCRIPTION ORDERS FOR CONTROLLED SUBSTANCES  
6 AS FOLLOWS:

7           1. PRESCRIPTION ORDERS FOR CONTROLLED SUBSTANCES LISTED IN SCHEDULES I  
8 AND II MUST BE MAINTAINED IN A SEPARATE PRESCRIPTION FILE FOR CONTROLLED  
9 SUBSTANCES LISTED IN SCHEDULES I AND II ONLY.

10          2. PRESCRIPTION ORDERS FOR CONTROLLED SUBSTANCES LISTED IN SCHEDULES  
11 III, IV AND V MUST BE MAINTAINED EITHER IN A SEPARATE PRESCRIPTION FILE FOR  
12 CONTROLLED SUBSTANCES LISTED IN SCHEDULES III, IV AND V ONLY OR IN A FORM  
13 THAT ALLOWS THEM TO BE READILY RETRIEVABLE FROM THE OTHER PRESCRIPTION  
14 RECORDS OF THE REGISTRANT. FOR THE PURPOSES OF THIS PARAGRAPH, "READILY  
15 RETRIEVABLE" MEANS THAT WHEN THE PRESCRIPTION IS INITIALLY FILED, THE FACE OF  
16 THE PRESCRIPTION IS STAMPED IN RED INK IN THE LOWER RIGHT CORNER WITH THE  
17 LETTER "C" IN A FONT THAT IS NOT LESS THAN ONE INCH HIGH AND THAT THE  
18 PRESCRIPTION IS FILED IN THE USUAL CONSECUTIVELY NUMBERED PRESCRIPTION FILE  
19 FOR NONCONTROLLED SUBSTANCE PRESCRIPTIONS. THE REQUIREMENT TO STAMP THE HARD  
20 COPY PRESCRIPTION WITH A RED "C" IS WAIVED IF A REGISTRANT EMPLOYS AN  
21 ELECTRONIC DATA PROCESSING SYSTEM OR OTHER ELECTRONIC RECORD KEEPING SYSTEM  
22 FOR PRESCRIPTIONS THAT PERMITS IDENTIFICATION BY PRESCRIPTION NUMBER AND  
23 RETRIEVAL OF ORIGINAL DOCUMENTS BY PRESCRIBER'S NAME, PATIENT'S NAME, DRUG  
24 DISPENSED AND DATE FILLED.

25          ~~B.~~ D. Except in emergency situations in conformity with subsection ~~G-~~  
26 E of this section, UNDER THE CONDITIONS SPECIFIED IN SUBSECTIONS F, G AND H  
27 OF THIS SECTION or when dispensed directly by a medical practitioner to an  
28 ultimate user, a controlled substance in schedule II shall not be dispensed  
29 without the written prescription order in ink or indelible pencil or  
30 typewritten and manually signed by the medical practitioner. A prescription  
31 order for a schedule II substance shall not be dispensed more than sixty days  
32 after the date on which the prescription order was issued. A prescription  
33 order for a schedule II substance shall not be refilled.

34          ~~G.~~ E. In emergency situations, emergency quantities of schedule II  
35 substances may be dispensed on an oral prescription order of a medical  
36 practitioner. Such an emergency prescription order shall be immediately  
37 reduced to writing by the pharmacist and shall contain all the information  
38 required for schedule II drugs except for the manual signing of the order by  
39 the medical practitioner. Within seven days after authorizing an emergency  
40 oral prescription order, the prescribing medical practitioner shall cause a  
41 written prescription order manually signed for the emergency quantity  
42 prescribed to be delivered to the dispensing pharmacist. In addition to  
43 conforming to other requirements for prescription orders for schedule II  
44 substances, it shall have written on its face "authorization for emergency  
45 dispensing" and the date of the oral order. If the prescribing medical

1 practitioner fails to deliver such an emergency prescription order within  
2 seven days in conformance with board rules, the pharmacist shall notify the  
3 board. Failure of the pharmacist to notify the board shall void the  
4 authority conferred by this subsection to dispense without a written,  
5 manually-signed prescription order of a medical practitioner.

6 F. THE FOLLOWING MAY BE TRANSMITTED TO A PHARMACY BY FACSIMILE BY A  
7 PATIENT'S MEDICAL PRACTITIONER OR THE MEDICAL PRACTITIONER'S AGENT:

8 1. A PRESCRIPTION ORDER WRITTEN FOR A SCHEDULE II NARCOTIC CONTROLLED  
9 SUBSTANCE TO BE COMPOUNDED FOR THE DIRECT ADMINISTRATION TO A PATIENT BY  
10 PARENTERAL, INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS OR INTRASPINAL INFUSION.

11 2. A PRESCRIPTION ORDER WRITTEN FOR ANY SCHEDULE II CONTROLLED  
12 SUBSTANCE FOR A RESIDENT OF A LONG-TERM CARE FACILITY.

13 3. A PRESCRIPTION ORDER WRITTEN FOR A SCHEDULE II NARCOTIC CONTROLLED  
14 SUBSTANCE FOR A PATIENT ENROLLED IN A HOSPICE CARE PROGRAM CERTIFIED OR PAID  
15 FOR BY MEDICARE UNDER TITLE XVIII OR A HOSPICE PROGRAM THAT IS LICENSED BY  
16 THIS STATE. THE MEDICAL PRACTITIONER OR THE MEDICAL PRACTITIONER'S AGENT  
17 MUST NOTE ON THE PRESCRIPTION THAT THE PATIENT IS A HOSPICE PATIENT.

18 G. A FACSIMILE TRANSMITTED PURSUANT TO SUBSECTION F OF THIS SECTION IS  
19 THE ORIGINAL WRITTEN PRESCRIPTION ORDER FOR PURPOSES OF THIS SECTION AND MUST  
20 BE MAINTAINED AS REQUIRED BY SUBSECTION C OF THIS SECTION.

21 ~~D.~~ H. Except when dispensed directly by a medical practitioner to an  
22 ultimate user, a controlled substance included in schedule III or IV which  
23 THAT requires a prescription order as determined under state or federal laws  
24 shall not be dispensed without a written or oral prescription order of a  
25 medical practitioner. The prescription order shall not be filled or refilled  
26 more than six months after the date on which the prescription order was  
27 issued. A prescription order authorized to be refilled shall not be refilled  
28 more than five times. Additional quantities may only be authorized by the  
29 prescribing medical practitioner through issuance of a new prescription order  
30 which shall be treated by the pharmacist as a new and separate prescription  
31 order.

32 ~~E.~~ I. Except when dispensed directly by a medical practitioner to an  
33 ultimate user, a controlled substance that is included in schedule V and that  
34 requires a prescription order as determined under state or federal laws shall  
35 not be dispensed without a written or oral prescription order of a medical  
36 practitioner. The prescription order may be refilled as authorized by the  
37 prescribing medical practitioner but shall not be filled or refilled more  
38 than one year after the date of issuance.

39 ~~F.~~ J. A controlled substance that is listed in schedule III, IV or V  
40 and that does not require a prescription order as determined under state or  
41 federal laws may be dispensed at retail by a pharmacist, ~~or~~ a pharmacy intern  
42 OR A GRADUATE INTERN under the pharmacist's supervision, without a  
43 prescription order to a purchaser at least eighteen years of age provided  
44 that all of the following are true:

45 1. It is for a legitimate medical purpose.

1           2. Not more than two hundred forty cubic centimeters (eight ounces) of  
2 any such controlled substance containing opium, nor more than one hundred  
3 twenty cubic centimeters (four ounces) of any other such controlled  
4 substance, nor more than forty-eight dosage units of any such controlled  
5 substance containing opium, nor more than twenty-four dosage units of any  
6 other controlled substance may be dispensed at retail to the same purchaser  
7 in any given forty-eight hour period.

8           3. No more than one hundred dosage units of any single active  
9 ingredient ephedrine preparation may be sold, offered for sale, bartered, or  
10 given away to any one person in any one thirty-day period.

11           4. The pharmacist, ~~or~~ pharmacy intern, ~~OR GRADUATE INTERN~~ requires  
12 every purchaser of a controlled substance under this subsection not known to  
13 ~~him~~ THAT PERSON to furnish suitable identification, including proof of age  
14 where appropriate.

15           5. A bound record book for dispensing controlled substances under this  
16 subsection is maintained by the pharmacist, ~~which book shall contain~~ AND  
17 CONTAINS the name and address of the purchaser, the name and quantity of the  
18 controlled substance purchased, the date of each purchase and the name or  
19 initials of the pharmacist, ~~or~~ pharmacy intern OR GRADUATE INTERN who  
20 dispensed the substance to the purchaser. Such book shall be maintained in  
21 conformity with the record keeping requirements of section 36-2523.

22           ~~G.~~ K. In the absence of a law requiring a prescription for a schedule  
23 V controlled substance, the board may by rules require, or remove the  
24 requirement of, a prescription order for a schedule V controlled substance.

25           ~~H.~~ L. The label on a container of a controlled substance directly  
26 dispensed by a medical practitioner or pharmacist, not for the immediate  
27 administration to the ultimate user, such as a bed patient in a hospital,  
28 shall bear the name and address of the dispensing medical practitioner or  
29 pharmacist, the serial number, date of dispensing, name of prescriber, name  
30 of patient or, if an animal, the name of the owner of the animal and the  
31 species of the animal, directions for use and cautionary statements, if any,  
32 contained in the prescription order or required by law. If the controlled  
33 substance is included in schedule II, III or IV the label shall bear a  
34 transfer warning to the effect: "Caution: federal law prohibits the  
35 transfer of this drug to any person other than the patient for whom it was  
36 prescribed".

37           ~~I.~~ M. The board ~~may~~, by rule, MAY provide additional requirements for  
38 prescribing and dispensing controlled substances.


APPROVED BY THE GOVERNOR APRIL 27, 2005.

FILED IN THE OFFICE OF THE SECRETARY OF STATE APRIL 27, 2005.

Passed the House April 20, 20 05,

by the following vote: 47 Ayes,


12 Nays, 1 Not Voting

  
Speaker of the House  
Pro Tempore  
Norman L. Fyone  
Chief Clerk of the House

Passed the Senate February 28, 20 05,

by the following vote: 28 Ayes,

0 Nays, 2 Not Voting

  
President of the Senate  
Champion Billington  
Secretary of the Senate

EXECUTIVE DEPARTMENT OF ARIZONA  
OFFICE OF GOVERNOR

This Bill was received by the Governor this

21<sup>st</sup> day of April, 20 05,


at 12:19 o'clock P. M.

Jennifer L. Parra  
Secretary to the Governor

Approved this 27 day of

April, 20 05,

at 10<sup>05</sup> o'clock A. M.

  
Governor of Arizona


S.B. 1126

EXECUTIVE DEPARTMENT OF ARIZONA  
OFFICE OF SECRETARY OF STATE

This Bill was received by the Secretary of State

this 27 day of April, 20 05

at 11:05 o'clock A. M.

  
Secretary of State